ALKYLAMINE OR HETEROALKYLAMINE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF

Abstract

The present invention provides NOS inhibitors such as iNOS inhibitors including alkylamine or heteroalkylamine derivatives, or a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, hydrate, or isomer thereof, in any crystalline form or in amorphous form. Pharmaceutical products comprising the NOS inhibitors such as iNOS inhibitors and the applications thereof in prophylaxis and/or treatment of inflammatory diseases, and proliferative diseases such as cancer including gastro-intestinal, colorectal, gynecological, pancreatic, head and neck, esophageal, breast, lung, and central nervous system tumors, among others, are also provided.

Claims

1. A compound represented by Formula (I-6), or a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, hydrate, or isomer thereof, in any crystalline form or in amorphous form: ##STR00074## wherein the waved line represents an alkyl chain or a heteroalkyl chain; R3 and R4 are independent of each other any monovalent group including hydro; R2 is any bivalent group or two hydro groups, and R1 and R5 are independent of each other any monovalent group including hydro or they together form a cyclic bivalent group, with a proviso that R1, R2, R3, R4 and R5 are not hydro, two hydro groups, phenyl, 2-cyano-5-cholrophenoxy and hydro respectively at the same time.

2. The compound according to claim 1, wherein the waved line represents an alkyl chain or a heteroalkyl chain selected from the following: ##STR00075##

3. The compound according to claim 1, wherein R1 and R5 are independent of each other selected from H, methyl, ethyl, methoxy methyl, methoxy ethyl, hydroxy methyl, and hydroxy ethyl; or NR5R1 form a cyclic bivalent group of: ##STR00076##

4. The compound according to claim 1, wherein R2 is two hydro groups or a NH2 group.

5. The compound according to claim 1, wherein R3 is selected from the following: ##STR00077## ##STR00078##

6. The compound according to claim 1, wherein R4 is selected from the following: ##STR00079## ##STR00080##

7. The compound according to claim 1, which is selected from the following compounds: ##STR00081## ##STR00082## ##STR00083## ##STR00084## ##STR00085## ##STR00086## ##STR00087## ##STR00088## ##STR00089## ##STR00090## ##STR00091## ##STR00092##

8. The compound according to claim 1, which is selected from the following compounds listed by increasing IC50: ##STR00093## ##STR00094##

9. The compound according to claim 1, which is selected from the following compounds listed by increasing IC50: ##STR00095##

10. The compound according to claim 1, which is selected from the following compounds listed by increasing aqueous solubility: ##STR00096##

11. The compound according to claim 1, which is selected from the following compounds listed by increasing aqueous solubility: ##STR00097##

12. A pharmaceutical composition, a kit, or a packaged pharmaceutical product comprising a therapeutically effective amount of the compound of Formula (I-6) according to claim 1, or a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, isomer, or hydrate thereof, in any crystalline form or in amorphous form, and a pharmaceutically acceptable carrier or excipient.

13. A method of using a compound of Formula (I-6) according to claim 1, or a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, isomer, or hydrate thereof, in any crystalline form or in amorphous form in medicine.

14. The method according to claim 13, which is a method of inhibiting one or more members selected from the family of nitric oxide synthases (NOS) including three isoforms inducible NOS (INOS), endothelial NOS (eNOS), and neuronal NOS (nNOS), comprising: contacting the NOS with an effective amount of a compound of Formula (I-6) according to claim 1, or a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, isomer, or hydrate thereof, in any crystalline form or in amorphous form.

15. The method according to claim 14, which is for selectively inhibiting (INOS) over eNOS and/or nNOS.

16. The method according to claim 13, which is a method for prophylaxis and/or treatment of a disorder or disease mediated by one or more members in the family of nitric oxide synthases (NOS) such as iNOS or associated with aberrant NOS activity such as iNOS activity, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I-6) according to claim 1, or a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, isomer, or hydrate thereof, in any crystalline form or in amorphous form; or a pharmaceutical composition thereof.

17. The method according to claim 16, wherein the disorder or disease is selected from inflammatory diseases, and proliferative diseases such as cancer including gastro-intestinal, colorectal, gynecological, pancreatic, head and neck, esophageal, breast, lung, and central nervous system tumors.

Description

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

[0014] The present invention is illustrated by way of example, and not by way of limitation, in the figures of the accompanying drawings and in which like reference numerals refer to similar elements. All the figures are schematic and generally only show parts which are necessary in order to elucidate the invention. For simplicity and clarity of illustration, elements shown in the figures and discussed below have not necessarily been drawn to scale. Well-known structures and devices are shown in simplified form, omitted, or merely suggested, in order to avoid unnecessarily obscuring the present invention.

[0015] FIG. 1 demonstrates a homology comparison between mouse iNOS (PDB 2Y37) and human iNOS (PDB INSI).

[0016] FIG. 2 shows compound AZ 6b as observed in mouse iNOS (PDB 2Y37) overlayed with a computationally guided induced fir docking (IFD) pose of AZ 6b.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

[0017] In the following description, for the purposes of explanation, numerous specific details are set forth in order to provide a thorough understanding of the present invention. It is apparent, however, to one skilled in the art that the present invention may be practiced without these specific details or with an equivalent arrangement.

[0018] At various places in the present specification, substituents of compounds of the invention are disclosed in groups or in ranges. It is specifically intended that the invention include each and every individual sub-combination of the members of such groups and ranges. For example, the term C.sub.1-6 alkyl is specifically intended to include C.sub.1 alkyl(methyl), C.sub.2 alkyl(ethyl), C.sub.3 alkyl, C.sub.4 alkyl, C.sub.5 alkyl, and C.sub.6 alkyl. Where a numerical range is disclosed herein, unless otherwise specified, such range is continuous, inclusive of both the minimum and maximum values of the range as well as every value between such minimum and maximum values. Still further, where a range refers to integers, only the integers from the minimum value to and including the maximum value of such range are included. In addition, where multiple ranges are provided to describe a feature or characteristic, such ranges can be combined.

[0019] The present invention provides a compound represented by Formula (I-6), or a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, hydrate, or isomer thereof, in any crystalline form or in amorphous form. Alkylamine or heteroalkylamine derivatives are represented by Formula (I-6), wherein the waved line represents an alkyl chain or a heteroalkyl chain; R3 and R4 are independent of each other any monovalent group including hydro; R2 is any bivalent group or two hydro groups, and R1 and R5 are independent of each other any monovalent group including hydro or they together form a cyclic bivalent group, with a proviso that R1, R2, R3, R4 and R5 are not hydro, two hydro groups, phenyl, 2-cyano-5-cholrophenoxy and hydro respectively at the same time:

##STR00004##

[0020] In exemplary embodiments, the waved line in Formula (I-6) represents an alkyl chain or a heteroalkyl chain selected from the following:

##STR00005##

[0021] The term monovalent non-hydrogen group may include, but is not limited to, groups in the following 8 classes.

[0022] Class (1): Halo or halogen group, i.e. F, Cl, Br or I; CN, NO2, N.sub.3, SO.sub.2H, SO.sub.3H, OH, OR, ONR.sub.2, NR.sub.2, NR.sub.3.sup.+X; N(OR)R, SH, SR, SSR, C(O)R, CO.sub.2H, CHO, C(OR).sub.2, CO.sub.2R, OC(O)R, OCO.sub.2R, C(O)NR.sub.2, OC(O)NR.sub.2, NRC(O)R, NRCO.sub.2R, NRC(O)NR.sub.2, C(NR)R, C(NR) OR, OC(NR)R, OC(NR) OR, C(NR) NR.sub.2, OC(NR) NR.sub.2, NRC(NR) NR.sub.2, C(O)NRSO.sub.2R, NRSO.sub.2R, SO.sub.2NR.sub.2, SO.sub.2R, SO.sub.2OR, OSO.sub.2R, S(O)R, OS(O)R, SIR.sub.3, OSiR.sub.3, C(S)NR.sub.2, C(O)SR, C(S)SR, SC(S)SR, SC(O)SR, OC(O)SR, SC(O) OR, SC(O)R, P(O).sub.2R, OP(O).sub.2R, P(O)R.sub.2, OP(O)R.sub.2, OP(O)(OR).sub.2, P(O)NR.sub.2, OP(O).sub.2NR.sub.2, P(O)(NR).sub.2, OP(O)(NR).sub.2, NRP(O)(OR).sub.2, NRP(O)(NR).sub.2, PR.sub.2, PR.sub.3, OPR.sub.2, OPR.sub.3, BR.sub.2, B(OR).sub.2, BR(OR), and the like. R is independently of each other any suitable group e.g. alkyl group. For example, OR may be an alkoxy or alkyloxy group, i.e. an O-alkyl group. The term C.sub.1-6 alkoxy/alkyloxy is an O(C.sub.1-6 alkyl) group. Examples of alkoxy include methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), tert-butoxy, and the like. The alkoxy or alkyloxy group optionally can be substituted by 1 or more (e.g., 1 to 5) suitable substituents.

[0023] Class (2): Alkyl group, i.e. saturated aliphatic hydrocarbon including straight chains and branched chains. In some embodiments, the alkyl group has 1 to 20 carbon atoms, 1 to 10 carbon atoms, 1 to 6 carbon atoms, or 1 to 4 carbon atoms. For example, the term C.sub.1-6 alkyl refers to linear or branched radicals of 1 to 6 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, or n-hexyl). An alkyl group optionally can be substituted by one or more (e.g., 1 to 5) suitable substituents.

[0024] Class (3): Alkenyl group, i.e. aliphatic hydrocarbon having at least one carbon-carbon double bond, including straight chains and branched chains having at least one carbon-carbon double bond. In some embodiments, the alkenyl group has 2 to 20 carbon atoms, 2 to 10 carbon atoms, 2 to 6 carbon atoms, 3 to 6 carbon atoms, or 2 to 4 carbon atoms. For example, the term C.sub.2-6 alkenyl includes straight or branched chain unsaturated radicals (having at least one carbon-carbon double bond) of 2 to 6 carbon atoms, including, but not limited to, ethenyl, 1-propenyl, 2-propenyl(allyl), isopropenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, and the like. An alkenyl group optionally can be substituted by one or more (e.g., 1 to 5) suitable substituents. The alkenyl group may exist as the pure E form, the pure Z form, or any mixture thereof.

[0025] Class (4): Alkynyl group, i.e. aliphatic hydrocarbons having at least one carbon-carbon triple bond, including straight chains and branched chains having at least one carbon-carbon triple bond. In some embodiments, the alkynyl group has 2 to 20, 2 to 10, 2 to 6, or 3 to 6 carbon atoms. For example, C.sub.2-6 alkynyl includes straight or branched hydrocarbon chain alkynyl radicals as defined above, having 2 to 6 carbon atoms. An alkynyl group optionally can be substituted by one or more (e.g., 1 to 5) suitable substituents.

[0026] Class (5): Cycloalkyl group may be saturated or unsaturated, non-aromatic, monocyclic or polycyclic (such as bicyclic) hydrocarbon rings (e.g., monocyclics such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or bicyclics including spiro, fused, or bridged systems (such as bicyclo[1.1.1]pentanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.2.1]octanyl or bicyclo[5.2.0]nonanyl, decahydronaphthalenyl, etc.). The cycloalkyl group has 3 to 15 carbon atoms. In some embodiments the cycloalkyl may optionally contain one, two or more non-cumulative non-aromatic double or triple bonds and/or one to three oxo groups. In some embodiments, the bicycloalkyl group has 6 to 14 carbon atoms. For example, C.sub.3-14 cycloalkyl includes saturated or unsaturated, non-aromatic, monocyclic or polycyclic (such as bicyclic) hydrocarbon rings of 3 to 14 ring-forming carbon atoms (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentanyl, or cyclodecanyl). The cycloalkyl group optionally can be substituted by 1 or more (e.g., 1 to 5) suitable substituents.

[0027] Class (6): Aryl group, i.e. all-carbon monocyclic or fused-ring polycyclic aromatic groups having a conjugated pi-electron system. The aryl group may have 6 or 10 carbon atoms in the ring(s). Most commonly, the aryl group has 6 carbon atoms in the ring. For example, C.sub.6-10 aryl is an aromatic radical containing from 6 to 10 carbon atoms such as phenyl or naphthyl. The aryl group optionally can be substituted by 1 or more (e.g., 1 to 5) suitable substituents.

[0028] Class (7): Heteroaryl group, i.e. monocyclic or fused-ring polycyclic aromatic heterocyclic groups with one or more heteroatom ring members (ring-forming atoms) each independently selected from O, S and N in at least one ring. The heteroaryl group has 5 to 14 ring-forming atoms, including 1 to 13 carbon atoms, and 1 to 8 heteroatoms selected from O, S, and N. In some embodiments, the heteroaryl group has 5 to 10 ring-forming atoms including one to four heteroatoms. The heteroaryl group can also contain one to three oxo or thiono (i.e., S) groups. In some embodiments, the heteroaryl group has 5 to 8 ring-forming atoms including one, two or three heteroatoms. For example, 5-membered heteroaryl group is a monocyclic heteroaryl group as defined above with 5 ring-forming atoms in the monocyclic heteroaryl ring; 6-membered heteroaryl is a monocyclic heteroaryl group as defined above with 6 ring-forming atoms in the monocyclic heteroaryl ring; 510-membered heteroaryl is a monocyclic or bicyclic heteroaryl group as defined above with 5, 6, 7, 8, 9 or 10 ring-forming atoms in the monocyclic or bicyclic heteroaryl ring. A heteroaryl group optionally can be substituted by 1 or more (e.g., 1 to 5) suitable substituents. Examples of monocyclic heteroaryls include those with 5 ring-forming atoms including one to three heteroatoms or those with 6 ring-forming atoms including one, two or three nitrogen heteroatoms. Examples of fused bicyclic heteroaryls include two fused 5- and/or 6-membered monocyclic rings including one to four heteroatoms. Examples of heteroaryl groups include pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, furyl, imidazolyl, pyrrolyl, oxazolyl (e.g., 1,3-oxazolyl, 1,2-oxazolyl), thiazolyl (e.g., 1,2-thiazolyl, 1,3-thiazolyl), pyrazolyl (e.g., pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl), tetrazolyl, triazolyl (e.g., 1,2,3-triazolyl, 1,2,4-triazolyl), oxadiazolyl (e.g., 1,2,3-oxadiazolyl), thiadiazolyl (e.g., 1,3,4-thiadiazolyl), quinolyl, isoquinolyl, benzothienyl, benzofuryl, indolyl, 1H-imidazo[4,5-c]pyridinyl, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-c]pyridinyl, imidazo[1,2-a]pyrazinyl, imidazo[2,1-c][1,2,4]triazinyl, imidazo[1,5-a]pyrazinyl, imidazo[1,2-a]pyrimidinyl, 1H-indazolyl, 9H-purinyl, imidazo[1,2-a]pyrimidinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, isoxazolo[5,4-c]pyridazinyl, isoxazolo[3,4-c]pyridazinyl, pyridone, pyrimidone, pyrazinone, pyrimidinone, 1H-imidazol-2 (3H)-one, 1H-pyrrole-2,5-dione, 3-oxo-2H-pyridazinyl, 1H-2-oxo-pyrimidinyl, 1H-2-oxo-pyridinyl, 2,4 (1H,3H)-dioxo-pyrimidinyl, 1H-2-oxo-pyrazinyl, and the like.

[0029] Class (8): Heterocycloalkyl group, i.e. monocyclic or polycyclic (including 2 or more rings that are fused together, including spiro, fused, or bridged systems, for example, a bicyclic ring system), saturated or unsaturated, non-aromatic 4- to 15-membered ring system including 1 to 14 ring-forming carbon atoms and 1 to 10 ring-forming heteroatoms each independently selected from O, S, N, P and B. The heterocycloalkyl group can also optionally contain one or more oxo (i.e., O) or thiono (i.e., S) groups. For example, 4- to 12-membered heterocycloalkyl is a monocyclic or polycyclic, saturated or unsaturated, non-aromatic 4- to 12-membered ring system that comprises one or more ring-forming heteroatoms. Examples of such heterocycloalkyl rings include azetidinyl, tetrahydrofuranyl, imidazolidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxazolidinyl, thiazolidinyl, pyrazolidinyl, thiomorpholinyl, tetrahydrothiazinyl, tetrahydrothiadiazinyl, morpholinyl, oxetanyl, tetrahydrodiazinyl, oxazinyl, oxathiazinyl, quinuclidinyl, chromanyl, isochromanyl, benzoxazinyl, 2-oxaspiro[3.3]heptyl {e.g., 2-oxaspiro[3.3]hept-6-yl}, 7-azabicyclo[2.2.1]heptan-1-yl, 7-azabicyclo[2.2.1]heptan-2-yl, 7-azabicyclo[2.2.1]heptan-7-yl, 2-azabicyclo[2.2.1]heptan-3-on-2-yl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl and the like. Further examples of heterocycloalkyl rings include tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyranyl (e.g., tetrahydro-2H-pyran-4-yl), imidazolidin-1-yl, imidazolidin-2-yl, imidazolidin-4-yl, pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, piperazin-2-yl, 1,3-oxazolidin-3-yl, 1,4-oxazepan-1-yl, isothiazolidinyl, 1,3-thiazolidin-3-yl, 1,2-pyrazolidin-2-yl, 1,2-tetrahydrothiazin-2-yl, 1,3-thiazinan-3-yl, 1,2-tetrahydrodiazin-2-yl, 1,3-tetrahydrodiazin-1-yl, 1,4-oxazin-4-yl, oxazolidinonyl, 2-oxo-piperidinyl (e.g., 2-oxo-piperidin-1-yl), 2-oxoazepan-3-yl, and the like. Some examples of aromatic-fused heterocycloalkyl groups include indolinyl, isoindolinyl, isoindolin-1-one-3-yl, 5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl, 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-6-yl, 4,5,6,7-tetrahydrothieno[2,3-c]pyridine-5-yl, 5,6-dihydrothieno[2,3-c]pyridin-7 (4H)-one-5-yl, 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-5-yl, and 3,4-dihydroisoquinolin-1 (2H)-one-3-yl groups. The heterocycloalkyl group is optionally substituted by 1 or more (e.g., 1 to 5) suitable substituents. Examples of heterocycloalkyl groups include 5- or 6-membered monocyclic rings and 9- or 10-membered fused bicyclic rings.

[0030] The term monovalent non-hydrogen group may include a combination of any number of groups selected from the above 8 classes. By a combination of two groups, it means that one group (G1) is substituted with another group (G2) to form a new group-G1-G2. By combination of three groups, it means that a first group (G1) is substituted with a second group (G2) which is substituted with a third group (G3), forming a new group -G1-G2-G3. For example, a group from Classes (2)-(8) may be substituted with a group from Class (1): (i) Haloalkyl group such as fluoroalkyl, i.e. an alkyl group having one or more halogen substituents such as F (up to perhaloalkyl, i.e., every hydrogen atom of the alkyl group has been replaced by a halogen atom). For example, C.sub.1-6 haloalkyl is a C.sub.1-6 alkyl group having one or more halogen substituents (up to perhaloalkyl, i.e., every hydrogen atom of the alkyl group has been replaced by a halogen atom). C.sub.1 haloalkyl is a methyl group having one, two, or three halogen substituents. (ii) Hydroxylalkyl or hydroxyalkyl, i.e. an alkyl group having one or more (e.g., 1, 2, or 3) OH substituents. (iii) Cyanoalkyl group, i.e an alkyl group having one or more (e.g., 1, 2, or 3) CN substituents. A group from Class (1) may be substituted with another group from Class (1), e.g. haloalkoxy group such as fluoroalkoxy, i.e. an O-haloalkyl group. C.sub.1-6 haloalkoxy refers to an O(C1-6 haloalkyl) group.

[0031] The term monovalent non-hydrogen group may also be any group selected from the above 8 classes and combination of any number of groups selected from the above 8 classes, that are substituted with one or more bivalent groups, i.e. two germinal hydrogens on a same atom are replaced with a group such as O, S, NNR.sub.2, NNRC(O)R, NNRC(O) OR, NNRS(O).sub.2R, NR, NOR, or the like.

[0032] Generally, the point of attachment of the monovalent non-hydrogen group can be from any suitable position. For example, piperidinyl can be piperidin-1-yl(attached through the N atom of the piperidinyl), piperidin-2-yl(attached through the C atom at the 2-position of the piperidinyl), piperidin-3-yl(attached through the C atom at the 3-position of the piperidinyl), or piperidin-4-yl(attached through the C atom at the 4-position of the piperidinyl). For another example, pyridinyl (or pyridyl) can be 2-pyridinyl (or pyridin-2-yl), 3-pyridinyl (or pyridin-3-yl), or 4-pyridinyl (or pyridin-4-yl). The point of attachment of the non-hydrogen monovalent group can be specified to indicate the position where the non-hydrogen monovalent group is attached to another moiety. For example, C.sub.1-2alkyl-(C.sub.3-4cycloalkyl) means the point of attachment occurs at the C.sub.1-2 alkyl part. For another example, (C.sub.3-4 cycloalkyl)C.sub.1-2 alkyl- also means the point of attachment occurs at the C.sub.1-2 alkyl part. When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any of the ring-forming atoms in that ring that are substitutable (i.e., one or more hydrogen atoms), unless otherwise specified or otherwise implicit from the context.

[0033] In some exemplary embodiments, R2 in Formula (I-6) is two hydro groups or a NH2 group. R1 and R5 in Formula (I-6) may be independent of each other selected from H, methyl, ethyl, methoxy methyl, methoxy ethyl, hydroxy methyl, and hydroxy ethyl; or NR5R1 form a cyclic bivalent group of

##STR00006##

[0034] In some exemplary embodiments, R3 in Formula (I-6) is selected from the following:

##STR00007## ##STR00008##

[0035] In some exemplary embodiments, R4 in Formula (I-6) is selected from the following:

##STR00009##

[0036] In some exemplary embodiments, the alkylamine or heteroalkylamine derivatives as represented by Formula (I-6) is selected from the following compounds:

##STR00010## ##STR00011## ##STR00012## ##STR00013## ##STR00014## ##STR00015## ##STR00016## ##STR00017##

##STR00018## ##STR00019## ##STR00020## ##STR00021##

[0037] In preferred embodiments, the alkylamine or heteroalkylamine derivatives as represented by Formula (I-6) is selected from the following compounds listed by increasing IC50: (GT-6064), (GT-6065), (GT-6041), (GT-6045), (GT-6059), (GT-6066), (GT-6060), and (GT-6058). In more preferred embodiments, the alkylamine or heteroalkylamine derivatives as represented by Formula (I-6) is selected from the following compounds listed by increasing IC50: (GT-6064) and (GT-6065).

[0038] In preferred embodiments, the alkylamine or heteroalkylamine derivatives as represented by Formula (I-6) is selected from the following compounds listed by increasing aqueous solubility: (GT-6058), (GT-6060), (GT-6066), (GT-6059), (GT-6045), (GT-6041), (GT-6065), and (GT-6064).

[0039] The present invention may include all pharmaceutically acceptable isotopically labelled compounds of Formula (I-6) or salts thereof, wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number which predominates in nature. Examples of isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as .sup.2H and .sup.3H, carbon, such as .sup.11C, .sup.13C and .sup.14C, chlorine, such as .sup.36Cl, fluorine, such as .sup.18F, iodine, such as .sup.123I and .sup.125I, nitrogen, such as .sup.13N and .sup.15N, oxygen, such as .sup.15O, .sup.17O and .sup.18O, phosphorus, such as .sup.32P, and sulfur, such as .sup.35S. Certain isotopically labelled compounds of Formula (I-6), for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, i.e., .sup.3H, and carbon-14, i.e., 14C, are particularly useful for this purpose in view of their ease of incorporation and detection. Substitution with heavier isotopes such as deuterium, i.e., .sup.2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances. Substitution with positron-emitting isotopes, such as .sup.11C, .sup.18F, .sup.150 and .sup.13N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy. Isotopically labeled compounds of Formula (I-6) can generally be prepared by conventional techniques known to those skilled in the art using an appropriate isotopically labeled reagent in place of the non-labeled reagent previously employed.

[0040] Regarding iosmers, some compounds of Formula (I-6) may include stereoisomers and tautomers, all of which are included within the scope of the invention. Stereoisomers of Formula (I-6) include cis and trans isomers, optical isomers such as R and S enantiomers, diastereomers, geometric isomers, rotational isomers, atropisomers, and conformational isomers of the compounds of Formula (I-6), including compounds exhibiting more than one type of isomerism; and mixtures thereof (such as racemates and diastereomeric pairs).

[0041] The compounds of Formula (I-6) may exist in the form of pharmaceutically acceptable salts such as acid addition salts and/or base salts thereof. Suitable acid addition salts are formed from acids which form non-toxic salts e.g. hydrochloride/chloride. Suitable base salts are formed from bases which form non-toxic salts such as calcium and sodium salts. Hemisalts of acids and bases may also be formed, for example, hemisulfate and hemicalcium salts.

[0042] The compounds of Formula (I-6) or a pharmaceutically acceptable salt thereof include all forms of the compound of Formula (I-6) or pharmaceutically salt thereof, including hydrates, solvates, isomers (e.g. rotational stereoisomers), crystalline and non-crystalline forms, isomorphs, polymorphs, metabolites, and prodrugs thereof. Compounds of Formula (I-6) may exist in unsolvated and solvated forms. When the solvent or water is tightly bound, the complex will have a well-defined stoichiometry independent of humidity. When, however, the solvent or water is weakly bound, as in channel solvates and hygroscopic compounds, the water/solvent content will be dependent on humidity and drying conditions.

[0043] The compounds of Formula (I-6) may exist in a continuum of solid states ranging from fully amorphous to fully crystalline. The term amorphous refers to a state in which the material lacks long-range order at the molecular level and, depending upon temperature, may exhibit the physical properties of a solid or a liquid. Typically, such materials do not give distinctive X-ray diffraction patterns and, while exhibiting the properties of a solid, are more formally described as a liquid. Upon heating, a change from apparent solid to a material with liquid properties occurs, which is characterized by a change of state, typically second order (glass transition). The term crystalline refers to a solid phase in which the material has a regular ordered internal structure at the molecular level and gives a distinctive X-ray diffraction pattern with defined peaks. Such materials when heated sufficiently will also exhibit the properties of a liquid, but the change from solid to liquid is characterized by a phase change, typically first order (melting point). The compounds of the invention may also exist in a mesomorphic state (mesophase or liquid crystal) when subjected to suitable conditions. The mesomorphic state is intermediate between the true crystalline state and the true liquid state (either melt or solution).

[0044] The invention also relates to prodrugs of the compounds of Formula (I-6). Some compounds of Formula (I-6) may have little or no pharmacological activity themselves, but they can, when administered into or onto the body, be converted into compounds of Formula (I-6) having the desired activity, for example, by hydrolytic cleavage. Such derivatives are referred to as prodrugs. Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the compounds of Formula (I-6) with certain moieties known to those skilled in the art as pro-moieties. In some embodiments, certain compounds of Formula (I-6) may themselves act as prodrugs of other compounds of Formula (I-6). Metabolites of compounds of Formula (I-6) formed in vivo upon administration of the drug are also included within the scope of the invention.

Preparation of Formula (I-6) Compounds

[0045] Starting materials and intermediates useful for making the compounds of the present invention can be obtained from chemical vendors or can be made according to methods described in the chemical art.

[0046] Compounds of the invention, including salts of the compounds, can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes. The reactions for preparing compounds of the invention can be carried out in suitable solvents, which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially non-reactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures that can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan.

[0047] Preparation of compounds of the invention may involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art. For example, a CN group can be hydrolyzed to afford an amide group; a carboxylic acid can be converted to an amide; a carboxylic acid can be converted to an ester, which in turn can be reduced to an alcohol, which in turn can be further modified. For another example, an OH group can be converted into a better leaving group such as a methanesulfonate, which in turn is suitable for nucleophilic substitution, such as by a cyanide ion. For another example, an S can be oxidized to S(O) and/or S(O).sub.2. For yet another example, an unsaturated bond such as C-C double bond or C-C triple bond can be reduced to a saturated bond by hydrogenation.

[0048] Functional (reactive) groups can be protected/deprotected in the course of the synthetic scheme, if appropriate and/or desired. For example, an OH group can be protected by a benzyl, methyl, or acetyl group, which can be deprotected and converted back to the OH group in a later stage of the synthetic process. For another example, an NH.sub.2 group can be protected by a benzyloxycarbonyl (Cbz) or BOC group; conversion back to the NH.sub.2 group can be carried out at a later stage of the synthetic process via deprotection.

[0049] Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as LCMS, nuclear magnetic resonance spectroscopy (e.g., .sup.1H or .sup.13C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry, or by chromatographic methods such as high-performance liquid chromatography (HPLC) or thin layer chromatography (TLC).

[0050] In some embodiments, the compounds of may exist as stereoisomers, such as atropisomers, racemates, enantiomers, or diastereomers. Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate using, for example, chiral high-performance liquid chromatography (HPLC). Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound contains an acidic or basic moiety, an acid or base such as tartaric acid or 1-phenylethylamine. The resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization, and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to one skilled in the art. Chiral compounds (and chiral precursors thereof) may be obtained in enantiomerically enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0% to 50% 2-propanol, typically from 2% to 20%, and from 0% to 5% of an alkylamine, typically 0.1% diethylamine. Concentration of the eluate affords the enriched mixture. Stereoisomeric conglomerates may be separated by conventional techniques known to those skilled in the art. Suitable stereoselective techniques are well known to those of ordinary skill in the art. For a compound of Formula (I-6) that contains an alkenyl or alkenylene group, geometric cis/trans (or Z/E) isomers are possible. Cis/trans isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallization.

Pharmaceutical Composition and Administration

[0051] The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of Formula (I-6), or a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, isomer, or hydrate thereof, in any crystalline form or in amorphous form, a pharmaceutically acceptable carrier or excipient, and optionally comprising at least one additional medicinal or pharmaceutical agent.

[0052] The pharmaceutically acceptable carrier or excipient may comprise any conventional pharmaceutical carrier or excipient. Suitable pharmaceutical carriers include inert diluents or fillers, water and various organic solvents such as hydrates and solvates. The pharmaceutical compositions may, if desired, contain additional ingredients such as flavorings, binders, excipients and the like.

[0053] The term therapeutically effective amount as used herein refers to that amount of the compound (including a pharmaceutically acceptable salt thereof) being administered which will relieve to some extent one or more of the symptoms of the disorder being treated. In reference to the prophylaxis and/or treatment of a disorder or disease mediated by NOS or associated with aberrant NOS activity, a therapeutically effective amount refers to that amount which has the effect of relieving to some extent or eliminating one or more symptoms associated with the NOS-mediated disease or disorder. The term treating /treatment, as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term treating /treatment also includes adjuvant and neo-adjuvant treatment of a subject.

[0054] Administration of the compounds of Formula (I-6) (including salts thereof) may be effected by any method that enables delivery of the compounds to the site of action. These methods include, for example, enteral routes (e.g., oral routes, buccal routes, sublabial routes, and sublingual routes), oral routes, intranasal routes, inhaled routes, intraduodenal routes, parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion), intrathecal routes, epidural routes, intracerebral routes, intracerbroventricular routes, topical, and rectal administration. In one embodiment of the present invention, the compounds of Formula (I-6) may be administered/effected by parenteral injection routes (e.g., intravenous injection route). In one embodiment of the present invention, the compounds of Formula (I-6) may be administered or effected by oral routes.

[0055] Dosage of the compounds of Formula (I-6) may be adjusted to provide the desired response. It is to be noted that dosage values may vary with the type and severity of the condition to be alleviated, and they may include single or multiple doses.

Kit or Packaged Pharmaceutical Product

[0056] The present invention provides a kit or packaged pharmaceutical product comprising a compound of Formula (I-6), or a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, isomer, or hydrate thereof, in any crystalline form or in amorphous form, and instructions for use thereof.

[0057] The kits (e.g., pharmaceutical packs) may include a provided pharmaceutical composition or compound and a container (e.g., a vial, ampule, bottle, syringe, and/or dispenser package, or other suitable containers). In some embodiments, the kits may optionally further include a second container comprising a pharmaceutical excipient for dilution or suspension of the pharmaceutical composition or compound. In some embodiments, a pharmaceutical composition or compound is provided in two containers, and when it is needed, the contents in the two containers are combined to form one unit dosage form.

Applications

[0058] The present invention provides a method of inhibiting one or more members selected from the family of nitric oxide synthases (NOS) including three isoforms inducible NOS (iNOS), endothelial NOS (eNOS), and neuronal NOS (nNOS), comprising contacting the NOS with an effective amount of a compound of Formula (I-6), or a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, isomer, or hydrate thereof, in any crystalline form or in amorphous form. In preferred embodiments, the present invention provides a method of selectively inhibiting (iNOS) over eNOS and/or nNOS.

[0059] The step of inhibiting may be carried out in vitro or in vivo. In vitro refers to procedures performed in an artificial environment such as, e.g., without limitation, in a test tube or culture medium. In vivo refers to procedures performed within a living organism such as, without limitation, a human, a mouse, dog, rat or rabbit.

[0060] As used herein, the term IC50 refers to the half maximal inhibitory concentration of an inhibitor in inhibiting biological or biochemical function. This quantitative measure indicates how much of a particular inhibitor is needed to inhibit a given biological process (or component of a process, i.e. an enzyme, cell, cell receptor or microorganism) by half. In other words, it is the half maximal (50%) inhibitory concentration (IC) of a substance (50% IC, or IC50). EC50 refers to the plasma concentration required for obtaining 50%> of a maximum effect in vivo.

[0061] In some embodiments, the method of the invention utilizes the NOS inhibitor of Formula (I-6) with an IC50 value of about or less than a predetermined value, as ascertained in an in vitro assay. In some embodiments, the inhibitor inhibits NOS (e.g. iNOS) with an IC50 value of about 0.01 M or less, 0.02 UM or less, 0.03 M or less, 0.04 M or less, 0.05 M or less, 0.06 M or less, 0.07 M or less, 0.08 M or less, 0.09 M or less, 0.1 M or less, 0.2 M or less, 0.4 M or less, 0.6 M or less, 0.8 M or less, 1 M or less, 2 M or less, 3 M or less, 4 M or less, 5 M or less, 10 M or less, 15 M or less, 20 M or less, or 25 M or less (or a number in the range defined by and including any two numbers above).

[0062] The present invention provides a method for prophylaxis and/or treatment of a disorder or disease mediated by NOS such as iNOS or associated with aberrant NOS such as iNOS activity, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I-6), or a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, isomer, or hydrate thereof, in any crystalline form or in amorphous form; or a pharmaceutical composition thereof.

[0063] As used herein, the term NOS-mediated disorder such as iNOS-mediated disorder means any disease, disorder, or other pathological condition in which NOS such as iNOS is known to play a role. Accordingly, in some embodiments, the present invention relates to treating or lessening the severity of one or more diseases in which NOS such as iNOS is known to play a role. The methods of the invention are useful for treating a disease condition associated with NOS such as iNOS. Any disease condition that results directly or indirectly from an abnormal activity or expression level of NOS such as iNOS can be an intended disease condition. Different disease conditions associated with NOS such as iNOS have been reported.

[0064] The disorder or disease includes inflammatory diseases, and proliferative diseases such as cancer including gastro-intestinal, colorectal, gynecological, pancreatic, head and neck, esophageal, breast, lung, and central nervous system tumors.

[0065] Compounds of Formula (I-6), as well as pharmaceutical compositions comprising them, can be administered to treat any of the described diseases, alone or in combination with a medical therapy. Medical therapies include, for example, surgery and radiotherapy (e.g. gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, systemic radioactive isotopes).

[0066] The invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of non-critical parameters that can be changed or modified to yield essentially the same results. Additional compounds within the scope of this invention may be prepared using the methods illustrated in these Examples, either alone or in combination with techniques generally known in the art.

EXAMPLES

Example 1: Molecular Design of Formula (I-6)

[0067] A crystal structure has been published with AZ 6b bound to mouse iNOS (PDB 2Y37). The inventors have compared mouse iNOS (PDB 2Y37) to human iNOS (PDB INSI). The inventors found that there is significant homology between this mouse iNOS or miNOS (PDB 2Y37) and published human iNOS or hiNOS (PDB INSI) with 22 of 23 residues in the active site binding region being identical (blue colored) as shown in FIG. 1, in which green parts are identical; red parts are different; and blue parts are highlighted pocket resides in both. The mouse iNOS PDB structure information was considered useful for being predictive in scoring designed inhibitors.

[0068] To rationally prioritize the molecular designs, a set of computational modeling procedures were carried out to estimate the potential binding affinity of the proposed molecules against the iNOS. Molecular docking is used to determine a binding affinity estimation in terms of docking score(S). The energy difference between the ground state conformation of the molecule vs. the predicted bound state (i.e. docked conformation) was estimated as well (dE).

[0069] CADD is carried out using Molecular Operating Environment (MOE) software, one of the top leading modeling software developed by Chemical Computing Group (https://www.chemcomp.com/). Both rigid receptors docking as well as induced fit docking (IFD) were conducted to each of the molecules, and a pharmacophore model was developed and applied to efficiently guide the docking procedure. The receptor template is described by the crystal complex with 6b bound in the pocket (PDB 2Y37). It was prepared by adding missing atoms and residues followed by fixing any bad contacts so that it is ready for the docking process.

[0070] The docking method was validated when the binding poses of AZ 6b observed in mouse iNOS (PDB 2Y37) was reproduced with an induced fit docking (IFD) operation on compound AZ 6b. FIG. 2 is compound AZ 6b as observed in published mouse iNOS PDB 2Y37 (cyan colored) overlayed with a computationally guided induced fir docking (IFD) pose of AZ 6b (yellow colored). The IFD binding energy S calculated for AZ 6b is-9.5 kcal. If designed molecules are near this binding energy, then they are hypothesized to bind nearly as well as AZ 6b and are candidates for synthesis and testing.

[0071] The docking score(S) from induced fit docking (IFD) with the guidance of a certain pharmacophore (F) for iNOS. The inventors used 3 features of the pharmacophore model (F3). The S are calculated based on the procedures of a very complicated yet sophisticated mathematics process. Basically, sample the possible conformations of both small molecules as well as receptors, followed by score ranking. All the theories are hard coded into the process of the module the inventors employed for the estimations.

[0072] As compared to compound AZ 6b, compounds of the invention show more potency, selective inhibition of iNOS vs. eNOS and nNOS, less toxicity and overall anti-inflammatory and anti-cancer efficacies.

[0073] In these embodiments, the inventors used a fused aromatic ring system to replace the W group within the patent WO2001062704 as indicated below. Claims in the patent WO2001062704 define the W-group as a single aromatic ring.

##STR00022##

[0074] A list of compound IDs and their SMILES codes are shown in Table I-6-1.

TABLE-US-00001 TABLE I-6-1 GT-ID SMILES Code GT-6001 NCCC(C1CCCCC1)CC2C(C#N)CNC(OC)C2 GT-6002 NCCC(C1CCCCC1)CC2C(C#N)CNC(C(F)(F)F)C2 GT-6003 NCCC(C1CCCCC1)CC2C(C#N)CNC(C)C2 GT-6004 CC1CC(CC(C2CCCCC2)CCNC)C(C#N)CN1 GT-6005 CC1CC(CC(C2CCCCC2)CCNCC)C(C#N)CN1 GT-6006 CC1CC(CC(C2CCCCC2)CCNCCOC)C(C#N)CN1 GT-6007 NC(SC(C1CCCCC1)CC2C(C#N)CCC(Cl)C2)[NH2+] GT-6008 NCCC(C1C(CNN2)C2NCN1)OC3C(C#N)CCC(Cl)C3 GT-6009 NCCC(C1NC(NNC2)C2CN1)OC3C(C#N)CCC(Cl)C3 GT-6010 NCCC(C1C(CNN2C)C2NCN1)OC3C(C#N)CCC(Cl)C3 GT-6011 NCCC(C1NC(N(C)NC2)C2CN1)OC3C(C#N)CCC(Cl)C3 GT-6012 NCCC(C1NC2NN(C)CC2CN1)OC3C(C#N)CCC(Cl)C3 GT-6013 NCCC(C1C(CNN2)C2CCC1)OC3C(C#N)CCC(Cl)C3 GT-6014 NCCC(C1CC(NNC2)C2CC1)OC3C(C#N)CCC(Cl)C3 GT-6015 NCCC(C1C(CNN2)C2NCC1)OC3C(C#N)CCC(Cl)C3 GT-6016 NCCC(C1NC(NNC2)C2CC1)OC3C(C#N)CCC(Cl)C3 GT-6017 NCCC(C1C(CNN2C)C2NCC1)OC3C(C#N)CCC(Cl)C3 GT-6018 NCCC(C1NC(N(C)NC2)C2CC1)OC3C(C#N)CCC(Cl)C3 GT-6019 NCCC(C1NC2NN(C)CC2CC1)OC3C(C#N)CCC(Cl)C3 GT-6020 NCCC(C1C(NCN2)C2NCN1)OC3C(C#N)CCC(Cl)C3 GT-6021 NCCC(C1NC(NCN2)C2CN1)OC3C(C#N)CCC(Cl)C3 GT-6022 NCCC(C1C(NCN2C)C2NCN1)OC3C(C#N)CCC(Cl)C3 GT-6023 NCCC(C1NC(N(C)CN2)C2CN1)OC3C(C#N)CCC(Cl)C3 GT-6024 NCCC(C1C(NCN2)C2CCC1)OC3C(C#N)CCC(Cl)C3 GT-6025 NCCC(C1CC(NCN2)C2CC1)OC3C(C#N)CCC(Cl)C3 GT-6026 NCCC(C1C(NCN2)C2NCC1)OC3C(C#N)CCC(Cl)C3 GT-6027 NCCC(C1NC(NCN2)C2CC1)OC3C(C#N)CCC(Cl)C3 GT-6028 NCCC(C1C(NCN2C)C2NCC1)OC3C(C#N)CCC(Cl)C3 GT-6029 NCCC(C1NC(N(C)CN2)C2CC1)OC3C(C#N)CCC(Cl)C3 GT-6030 NCCC(C1CN2C(CC1)CCN2)OC3C(C#N)CCC(Cl)C3 GT-6031 NCCC(C1CN2C(CC1)CNC2)OC3C(C#N)CCC(Cl)C3 GT-6032 NCCC(C1CN2C(CC1)NCC2)OC3C(C#N)CCC(Cl)C3 GT-6033 NCCC(C1CC2CCNN2CC1)OC3C(C#N)CCC(Cl)C3 GT-6034 NCCC(C1CC2CNCN2CC1)OC3C(C#N)CCC(Cl)C3 GT-6035 NCCC(C1CC2NCCN2CC1)OC3C(C#N)CCC(Cl)C3 GT-6036 N#CC1C(OC(C2CC3NCCN3CC2)CCNC)CC(Cl)CC1 GT-6037 N#CC1C(OC(C2CC(CNN3C)C3CC2)CCNC)CC(Cl)CC1 GT-6038 N#CC1C(OC(C2CC3CN(C)NC3CC2)CCNC)CC(Cl)CC1 GT-6039 N#CC1C(OC(C2CC(CNN3)C3CC2)CCNC)CC(Cl)CC1 GT-6040 NCC[C@H](C1CCCCC1)OC2C3C(CNC3O)CC(Cl)C2 GT-6041 NCC[C@H](C1CCCCC1)OC2C3C(NCN3)CC(Cl)C2 GT-6042 NCC[C@H](C1CCCCC1)OC2C3C(CC(N3)O)CC(Cl)C2 GT-6043 NCC[C@H](C1CCCCC1)OC2C3C(NC(C3)O)CC(Cl)C2 GT-6044 NCC[C@H](C1CCCCC1)NC2C3C(NC(C3)O)CC(Cl)C2 GT-6045 NCC[C@H](C1CCCCC1)OC2C3C(NNC3)CC(Cl)C2 GT-6046 NCC[C@H](C1CCCCC1)OC2CC(Cl)CC3NNCC32 GT-6047 NCC[C@H](C1CCCCC1)OC2C3C(CNN3)CC(Cl)C2 GT-6048 NCC[C@H](C1CCCCC1)OC2CC(Cl)CC3CNNC32 GT-6049 NCC[C@H](C1CCCCC1)OC2C3C(NNN3)CC(Cl)C2 GT-6050 NCC[C@H](C1CCCCC1)OC2CC(Cl)CC3NNNC32 GT-6051 NCC[C@H](C1CCCCC1)OC2C3C(NNN3)CC(Cl)C2 GT-6052 NCC[C@H](C1CCCCC1)OC2CC(Cl)CN3C2NCC3 GT-6053 NCC[C@H](C1CCCCC1)OC2CC(Cl)CC3NCCN32 GT-6054 NCC[C@H](C1CCCCC1)OC2CC(Cl)CN3C2CNC3 GT-6055 NCC[C@H](C1CCCCC1)OC2CC(Cl)CC3CNCN32 GT-6056 NCC[C@H](C1CCCCC1)OC2CC(Cl)CN3C2CCN3 GT-6057 NCC[C@H](C1CCCCC1)OC2CC(Cl)CC3CCNN32 GT-6058 C1C1CC(O[C@@H](C2CCCCC2)CCNC)C3C(NCN3)C1 GT-6059 C1C1CC(O[C@@H](C2CCCCC2)CCNC)C3C(NNC3)C1 GT-6060 C1C1CC(O[C@@H](C2CCCCC2)CCNCCO)C3C(NCN3)C1 GT-6061 C1C1CC(O[C@@H](C2CCCCC2)CCNCCO)C3C(NNC3)C1 GT-6062 C1C1CC(OC(C2CC(N)NCC2)CCNC)C(C#N)CC1 GT-6063 N#CC1C(OC(C2CC(N)NCC2)CCN3C(C(CCCC4)C4C3O)O)CC(Cl)CC1 GT-6064 NCCC(C1CC(N)NCC1)OC2C(C#N)CCC(Cl)C2 GT-6065 N#CC1C(OC(C2CC3NCCN3CC2)CCN4C(C(CCCC5)C5C4O)O)CC(Cl)CC1 GT-6066 C1C1CC(O[C@@H](C2CCCCC2)CCN3C(C(CCCC4)C4C3O)O)C5C(NNC5)C1

[0075] The compound physical property calculations including molecular weight (MW), cLogP, TPSA, as well as energy values S_IFD_F3_iNOS and dE iNOS binding conf-ground state conf are provided in Table I-6-2.

TABLE-US-00002 TABLE I-6-2 Binding energy dE iNOS binding CD CD (S_IFD_F3_iNOS) conf-ground state GT-ID MW clogP TPSA (kcal) conf (kcal) GT-6001 9.3 9.4 GT-6002 9.7 10.0 GT-6003 9.2 9.2 GT-6004 9.5 10.1 GT-6005 9.6 13.2 GT-6006 10.0 17.8 GT-6007 9.1 10.2 GT-6008 9.3 5.6 GT-6009 9.2 4.1 GT-6010 9.5 7.3 GT-6011 9.7 5.4 GT-6012 9.9 4.3 GT-6013 9.3 5.3 GT-6014 9.5 8.6 GT-6015 9.3 5.3 GT-6016 9.4 8.2 GT-6017 9.9 7.0 GT-6018 341 2.1 87 9.9 5.5 GT-6019 9.2 4.4 GT-6020 9 5.0 GT-6021 9.6 9.2 GT-6022 9.5 4.1 GT-6023 9.6 6.9 GT-6024 9.3 8.8 GT-6025 9.7 8.2 GT-6026 9.2 8.3 GT-6027 8.9 5.8 GT-6028 9.8 8.4 GT-6029 9.2 7.3 GT-6030 9.5 8.8 GT-6031 9.6 5.0 GT-6032 9.6 6.9 GT-6033 9.5 5.4 GT-6034 9.5 5.1 GT-6035 327 3 75 9.7 3.4 GT-6036 340 3.2 61 9.7 4.4 GT-6037 354 3.5 61 9.9 4.7 GT-6038 354 3.5 61 9.9 7.3 GT-6039 341 3.4 69 9.6 7.8 GT-6040 317 3 64 8.3 12.2 GT-6041 302 3.7 60 8.6 9.7 GT-6042 317 2.8 64 8.4 6.3 GT-6043 317 2.8 64 8.6 7.7 GT-6044 316 2.2 67 8.4 13.6 GT-6045 302 3.9 60 9.2 4.9 GT-6046 302 3.9 60 8.3 7.3 GT-6047 302 3.9 60 8.6 3.5 GT-6048 302 3.9 60 8.5 9.2 GT-6049 303 3.5 72 8.7 4.7 GT-6050 303 3.2 72 8.3 6.1 GT-6051 303 3.5 72 8.6 3.1 GT-6052 302 3.5 51 8.6 10.2 GT-6053 302 3.5 51 8.6 3 GT-6054 302 3.5 51 9 18.3 GT-6055 302 3.5 51 8.7 7.3 GT-6056 302 3.5 51 8.1 3 GT-6057 302 3.5 51 8.7 8.5 GT-6058 316 4 46 GT-6059 316 4.2 46 GT-6060 346 3.5 66 GT-6061 346 3.7 66 GT-6062 316 2.1 83 GT-6063 432 3.9 109 GT-6064 302 1.9 97 GT-6065 456 5 86 GT-6066 431 5.9 71

[0076] GT-6035, -6036, -6037, -6038 and -6039 test whether a fused aromatic ring will work as a replacement for the single aromatic ring in the patent WO2001062704. Notably, compound GT-6035 had the most optimal energetic calculations for all designed molecules with the IFD energy of binding determined to be 9.7 kcal and the difference from ground state to bound state, dE calculated at 3.3 kcal. Low values in the latter indicate a low energy barrier for the molecule to assume the bound conformation and hence might be an indication of a favorable inhibitor. The other members of this class test small changes to the molecule to see where potency might be further improved.

Example 2: Synthesis of Formula (I-6) Compounds

[0077] Some compounds of the invention identified by the following ID codes GT-XXXX are also identified by ID codes CPG-YYY, as listed in Table S-1.

TABLE-US-00003 TABLE S-1 GT-XXXX CPG-YYY AZ 6b CPG-6B GT-6035 CPG-195 GT-6065 CPG-264 GT-6036 CPG-200 GT-6041 CPG-224 GT-6058 CPG-255 GT-6059 CPG-256 GT-6060 CPG-257 GT-6061 CPG-258 GT-6064 CPG-263 GT-6066 CPG-265

Synthesis of (R)-2-(3-amino-1-phenylpropoxy)-4-chlorobenzonitrile (CPG-6B)

##STR00023##

Step 1: Synthesis of (R)-3-azido-1-phenylpropan-1-ol (2)

##STR00024##

[0078] A mixture of (R)-3-chloro-1-phenylpropan-1-ol (5 g, 29.4 mmol) and NaN3 (3.22 g, 33 mmol) in DMSO (30 mL) was stirred at 40 degrees for 1.5 h. LCMS was used to monitor this reaction. The reaction mixture was partitioned between water (30 mL) and EtOAc (50 mL). The organic phase was separated, washed with water (20 mL) and brine (20 mL), dried over anhydrous Na.sub.2SO.sub.4 and concentrated to get the crude product, which was purified by column chromatography on silica gel (EA/.PE from 0/100 to 1/1) to get the pure (R)-3-azido-1-phenylpropan-1-ol (4.1 g, 78% yield) as a colorless oil. LCMS: m/z 178.1 [M+H]+.

Step 2. Synthesis of (R)-2-(3-azido-1-phenylpropoxy)-4-chlorobenzonitrile (3)

##STR00025##

[0079] To a solution of (R)-3-azido-1-phenylpropan-1-ol (1 g, 5.65 mmol) and 4-chloro-2-fluorobenzonitrile (0.88 g, 5.65 mmol) in dried THF (20 mL) was treated with NaH (60%, 5.65 mmol, 0.226 g) at room temperature under N.sub.2 atmosphere. The mixture was stirred at 60 C. for 1.5 h. LCMS was used to monitor this reaction. The reaction mixture was partitioned between water (30 mL) and EtOAc (50 mL). The organic phase was separated, washed with water (20 mL) and brine (20 mL), dried over anhydrous Na.sub.2SO.sub.4 and concentrated to get the crude product, which was purified by column chromatography on silica gel (EA/.PE from 0/100 to 1/10) to get the pure (R)-2-(3-azido-1-phenylpropoxy)-4-chlorobenzonitrile (1.41 g, 80% yield) as a colorless oil. LCMS: m/z 313.1 [M+H]+.

Step 3. Synthesis of (R)-2-(3-amino-1-phenylpropoxy)-4-chlorobenzonitrile (4)

##STR00026##

[0080] To a solution of (R)-2-(3-azido-1-phenylpropoxy)-4-chlorobenzonitrile (500 mg, 1.6 mmol) in THF (10 mL) and water (0.1 mL) was added PPh3 (226 mg) in portions. The reaction solution was stirred at room temperature overnight. The solvent was evaporated, and the residue was purified by column chromatography on silica gel (EA, then 10% 7N NH3 in MeOH/DCM). The oil obtained was converted into HCl salt using 1 eq. aq. HCl to afford the pure (R)-2-(3-amino-1-phenyl propoxy)-4-chlorobenzonitrile (258 mg, 50% yield) as a white solid. LCMS: m/z 287.1 [M+H]+. 1H NMR(400 MHZ, DMSO) 7.96 (s, 3H), 7.79 (d, J=8.3 Hz, 1H), 7.47-7.39 (m, 4H), 7.39-7.31 (m, 1H), 7.21 (d, J=1.7 Hz, 1H), 7.16 (dd, J=8.3, 1.8 Hz, 1H), 5.86 (dd, J=8.1, 4.7 Hz, 1H), 2.95-2.85 (m, 2H), 2.35-2.23 (m, 1H), 2.22-2.02 (m, 1H).

Synthesis of 2-(3-amino-1-(imidazo[1,2-a]pyridin-7-yl) propoxy)-4-chlorobenzonitrile (CPG-195)

##STR00027##

Step 1. Synthesis of tert-butyl (4-(3-(1,3-dioxoisoindolin-2-yl)-1-hydroxypropyl) pyridin-2-yl) carbamate (3)

##STR00028##

[0081] To a solution of tert-butyl (4-bromopyridin-2-yl) carbamate (1.34 g, 4.92 mmol) in THF (15 mL) was added n-BuLi (2.5 M, 3.94 mL, 9.85 mmol) at 78 C. and the mixture was stirred at 78 C. for 30 min. Then a solution of 3-(1,3-dioxoisoindolin-2-yl) propanal (1.0 g, 4.92 mmol) in THF (5 mL) was added dropwise to the above mixture at 78 C. and the mixture was stirred at room temperature for 12 hrs. Sat. NaCl solution (20 mL) was added to the mixture and the mixture was extracted with EA (20 mL3). The organic layer was washed with brine (15 mL), dried over anhydrous Na.sub.2SO.sub.4, filtered and concentrated. The residue was purified by silica gel column (EA in PE=0% to 30%) to give tert-butyl (4-(3-(1,3-dioxoisoindolin-2-yl)-1-hydroxypropyl)pyridin-2-yl) carbamate (3) (556 mg, 1.4 mmol, 28.5% yield) as colorless oil. LCMS: m/z 398.3 [M+H]+1H NMR(400 MHZ, CDCl3) 8.18 (d, J=5.2 Hz, 1H), 7.89-7.84 (m, 3H), 7.75 (dd, J=5.6, 3.2 Hz, 3H), 7.02 (d, J=5.2 Hz, 1H), 4.69-4.61 (m, 1H), 3.99-3.92 (m, 2H), 3.43 (d, J=4.4 Hz, 1H), 2.14-2.03 (m, 1H), 1.98-1.96 m, 1H), 1.55-1.48 (m, 9H).

Step 2. Synthesis of tert-butyl (4-(1-(5-chloro-2-cyanophenoxy)-3-(1,3-dioxoisoindolin-2-yl) propyl)pyridin-2-yl) carbamate (4)

##STR00029##

[0082] To a solution of tert-butyl (4-(3-(1,3-dioxoisoindolin-2-yl)-1-hydroxypropyl)pyridin-2-yl) carbamate (449 mg, 1.13 mmol), Et3N (228 mg, 2.26 mmol) in DCM (20 mL) was added MsCl (155 mg, 1.356 mmol) at 0 C. and the mixture was stirred at room temperature for 2 h. The solvent was removed to give 1-(2-((tert-butoxycarbonyl)amino)pyridin-4-yl)-3-(1,3-dioxo isoindolin-2-yl) propyl methanesulfonate (990 mg, crude) as yellow oil. A solution of 1-(2-((tert-butoxycarbonyl)amino)pyridin-4-yl)-3-(1,3-dioxoisoindolin-2-yl) propyl methanesulfonate (990 mg, crude) in DMF (2 mL) was added to a mixture of 4-chloro-2-hydroxybenzonitrile (174 mg, 1.13 mmol) and Cs2CO.sub.3 (441 mg, 1.356 mmol) in DMF (8 mL) at 70 C. and the mixture was stirred at 70 C. for 12 hrs. Water (100 mL) was added to the reaction mixture at 0 C. and the suspension was stirred for 30 min. The suspension mixture was filtered to give tert-butyl (4-(1-(5-chloro-2-cyanophenoxy)-3-(1,3-dioxoisoindolin-2-yl) propyl)pyridin-2-yl) carbamate (530 mg, crude) as a yellow solid. LCMS: m/z 533.1 [M+H]+.

Step 3. Synthesis of 2-(1-(2-aminopyridin-4-yl)-3-(1,3-dioxoisoindolin-2-yl) propoxy)-4-chlorobenzonitrile (5)

##STR00030##

[0083] To a solution of tert-butyl (4-(1-(5-chloro-2-cyanophenoxy)-3-(1,3-dioxoisoindolin-2-yl) propyl)pyridin-2-yl) carbamate (530 mg, 0.996 mmol) in DCM (15 mL) was added TFA (10 mL) at 0 C. and the mixture was stirred at room temperature for 12 hrs. The solvent was removed, and the residue was dissolved with DCM (10 mL) and pH of the mixture was adjusted to 8-9 with a solution of NH3 in MeOH (7 M). Then the solvent was removed, and the residue was purified by silica gel column chromatography (MeOH in DCM=0% to 15%) to give 2-(1-(2-aminopyridin-4-yl)-3-(1,3-dioxoisoindolin-2-yl) propoxy)-4-chlorobenzonitrile (5) (400 mg, 0.926 mmol, 93% yield) as yellow oil. LCMS: m/z 433.1 [M+H]+. 1H NMR(400 MHZ, CDCl3) 8.03 (d, J=5.6 Hz, 1H), 7.83 (dd, J=5.6, 3.2 Hz, 2H), 7.72 (dd, J=5.6, 3.2 Hz, 2H), 7.57-7.55 (m, 1H), 6.98 (dd, J=8.4, 1.6 Hz, 1H), 6.70 (d, J=1.6 Hz, 1H), 6.62 (d, J=5.2 Hz, 1H), 6.49 (s, 1H), 5.12 (dd,J=8.8, 4.0 Hz, 1H), 4.53 (s, 2H), 4.03-3.93 (m, 2H), 2.52-2.39 (m, 1H), 2.24-2.17 (m, 1H).

Step 4. Synthesis of 4-chloro-2-(3-(1,3-dioxoisoindolin-2-yl)-1-(imidazo[1,2-a]pyridin-7-yl) propoxy)benzonitrile (CPG-264)

##STR00031##

[0084] A mixture of 2-(1-(2-aminopyridin-4-yl)-3-(1,3-dioxoisoindolin-2-yl) propoxy)-4-chlorobenzonitrile (250 mg, 0.577 mmol), a solution of aqueous 2-chloroacetaldehyde (40% w/w, 6.1 mol/L, 0.11 mL, 0.693 mmol) in EtOH (10 mL) was stirred in a sealed tube at 70 C. for 12 hrs. The solvent was removed, and the residue was azeotroped with additional EtOH (10 mL) to remove the residual water to give 4-chloro-2-(3-(1,3-dioxoisoindolin-2-yl)-1-(imidazo[1,2-a]pyridin-7-yl) propoxy)benzonitrile (CPG-264) (264 mg, crude) as a white solid, which will be used in next step without further purification.

[0085] The crude product (100 mg) was purified by Prep-HPLC (Fluent with 0.2% FA and ACN) to give 4-chloro-2-(3-(1,3-dioxoisoindolin-2-yl)-1-(imidazo[1,2-a]pyridin-7-yl) propoxy)benzonitrile (CPG-264) (40.4 mg, 0.088 mmol, 38.5% yield) as a white solid, which has been delivered. LCMS: m/z 457.1 [M+H]+. 1H NMR(400 MHZ, MeOD) 8.21 (d, J=5.2 Hz, 1H), 7.91 (s, 1H), 7.64 (d, J=8.0 Hz, 1H), 7.11-6.96 (m, 3H), 5.53-5.49 (m, 1H), 3.58-3.55 (m, 1H), 3.51-3.48 (m, 1H), 2.86 (s, 3H), 2.28-2.23 (m, 2H), 1.53 (s, 9H), 1.43 (s, 9H).

Step 5. Synthesis of 2-(3-amino-1-(imidazo[1,2-a]pyridin-7-yl) propoxy)-4-chlorobenzonitrile (CPG-195)

##STR00032##

[0086] A mixture of 4-chloro-2-(3-(1,3-dioxoisoindolin-2-yl)-1-(imidazo[1,2-a]pyridin-7-yl) propoxy)benzonitrile (164 mg, crude) and hydrazine hydrate (0.52 mL, 10.77 mmol) in EtOH (10 mL) was stirred at 80 C. for 12 hrs. The solvent was removed under reduced pressure. The residue was purified by Prep-HPLC (Fluent with 10 mM NH4HCO3 and ACN) to give 2-(3-amino-1-(imidazo[1,2-a]pyridin-7-yl) propoxy)-4-chlorobenzonitrile (CPG-195) (12.8 mg, 0.039 mmol, 10.9% yield) as yellow oil. LCMS: m/z 327.0 [M+H]+. 1HNMR(400 MHZ, MeOD) 8.51 (d, J=7.2 Hz, 1H), 7.86 (s, 1H), 7.64 (d, J=8.4 Hz, 1H), 7.60 (s, 2H), 7.15 (s, 1H), 7.12-7.08 (m, 1H), 7.00 (d, J=7.2 Hz, 1H), 5.75 (dd, J=8.4, 4.0 Hz, 1H), 3.17-3.14 (m, 2H), 2.49-2.39 (m, 1H), 2.35-2.25 m, 1H).

Synthesis of 5-(2-chloroacetyl)N-(2-chlorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-3-carboxamide (CPG-200)

##STR00033##

Step 1. Synthesis of tert-butyl (3-(methoxy(methyl)amino)-3-oxopropyl) (methyl) carbamate (2)

##STR00034##

[0087] To a mixture of 3-((tert-butoxycarbonyl) (methyl)amino) propanoic acid (1.0 g, 4.92 mmol) and N,O-Dimethylhydroxylamine hydrochloride (479 mg, 4.92 mmol) and DIPEA (1.9 g, 14.7 mmol) in DMF (30 mL) was added HATU (2.8 g, 7.38 mmol) at room temperature and the mixture was stirred at room temperature for 3 hrs. The mixture was quenched with by adding water (50 mL). The mixture was extracted with EtOAc (100 mL3). The combined organic layer was washed with 0.5 M HCl solution (100 mL) and then sat. NaHCO.sub.3 (50 mL) and brine (50 mL), dried over anhydrous Na.sub.2SO.sub.4, filtered and concentrated to give tert-butyl (3-(methoxy(methyl)amino)-3-oxopropyl) (methyl) carbamate (2) (2.3 g, 64% yield) as colorless oil. 1H NMR (400 MHz, CDCl.sub.3) 3.70 (d, J=8.0 Hz, 3H), 3.52 (s, 2H), 3.19 (s, 3H), 2.89 (s, 3H), 2.67 (s, 2H), 1.46 (s, 9H).

Step 2. Synthesis of tert-butyl (3-(2-((tert-butoxycarbonyl)amino)pyridin-4-yl)-3-oxopropyl) (methyl) carbamate (3)

##STR00035##

[0088] To a solution of tert-butyl (4-bromopyridin-2-yl) carbamate (1.66 g, 6.08 mmol) in THF (30 mL) was added dropwise n-BuLi (2.5M, 4.9 mL, 12.18 mmol) at 78 C. and the mixture was stirred at 78 C. for 30 min. Then a solution of tert-butyl (3-(methoxy(methyl)amino)-3-oxopropyl) (methyl) carbamate (1.5 g, 6.08 mmol) in THF (5 mL) was added dropwise to the above mixture at 78 C. and the mixture was stirred at 78 C. for 1 hr. The saturated NaCl solution (20 mL) was added to the mixture and the mixture was extracted with EtOAc (20 mL3). The organic layer was washed with brine (10 mL), dried over anhydrous Na.sub.2SO.sub.4, filtered and concentrated to give desired product (2.1 g crude) as pale-yellow oil, which will be used in next step without further purification. LCMS: m/z 380.3 [M+H]+.

Step 3. Synthesis of tert-butyl (3-(2-((tert-butoxycarbonyl)amino)pyridin-4-yl)-3-hydroxypropyl) (methyl) carbamate (4)

##STR00036##

[0089] To a mixture of tert-butyl (3-(2-((tert-butoxycarbonyl)amino)pyridin-4-yl)-3-oxopropyl) (methyl) carbamate (2.1 g, 5.53 mmol) in methanol (20 mL) was added NaBH4 (209 mg, 5.53 mmol) at 0 C. and the mixture was stirred at 0 C. for 10 min. The solvent was removed, and the residue was purified by column chromatography (MeOH in DCM=0% to 18%) to give tert-butyl (3-(2-((tert-butoxycarbonyl)amino)pyridin-4-yl)-3-hydroxypropyl) (methyl) carbamate (4) (1.1 g, crude) as a yellow oil. LCMS: m/z 382.3 [M+H]+. 1H NMR(400 MHZ, DMSO) 9.66 (s, 1H), 8.13 (d, J=4.8 Hz, 1H), 7.80 (s, 1H), 6.95 (d, J=4.0 Hz, 1H), 5.44 (d, J=4.4 Hz, 1H), 4.53-4.51 (m, 1H), 3.20-3.14 (m, 2H), 2.77 (s, 3H), 1.82-1.75 (m, 2H), 1.46 (s, 9H), 1.38 (s, 9H).

Step 4. Synthesis of tert-butyl (3-(2-((tert-butoxycarbonyl)amino)pyridin-4-yl)-3-(5-chloro-2-cyanophenoxy) propyl) (methyl) carbamate (5)

##STR00037##

[0090] To a mixture of tert-butyl (3-(2-((tert-butoxycarbonyl)amino)pyridin-4-yl)-3-hydroxypropyl) (methyl) carbamate (1.1 g, 2.88 mmol), 4-chloro-2-hydroxybenzonitrile (660 mg, 5.68 mmol) in THF (30 mL) was added triphenylphosphine (1.36 g, 5.18 mmol) and then dropwise DEAD (902 mg, 5.18 mmol) at 0 C. and the mixture was stirred at room temperature for 12 hrs. The mixture was quenched with water (15 mL) and extracted with EtOAc (30 mL2). The organic layers were washed with brine (10 mL), dried over anhydrous Na.sub.2SO.sub.4, filtered, concentrated. The residue was purified by column chromatography with a gradient of EtOAc/petroleum ether (0 to 50 percent) to give tert-butyl (3-(2-((tert-butoxycarbonyl)amino)pyridin-4-yl)-3-(5-chloro-2-cyanophenoxy) propyl) (methyl) carbamate (5) (420 mg, 0.814 mmol, 28.2% yield) as yellow oil. . . . LCMS: m/z 517.1 [M+H]+. 1H NMR(400 MHZ, MeOD) 8.21 (d, J=5.2 Hz, 1H), 7.91 (s, 1H), 7.64 (d, J=8.0 Hz, 1H), 7.11-6.96 (m, 3H), 5.53-5.49 (m, 1H), 3.58-3.55 (m, 1H), 3.51-3.48 (m, 1H), 2.86 (s, 3H), 2.28-2.23 (m, 2H), 1.53 (s, 9H), 1.43 (s, 9H).

Step 5. Synthesis of 2-(1-(2-aminopyridin-4-yl)-3-(methylamino) propoxy)-4-chlorobenzonitrile (6)

##STR00038##

[0091] To a mixture of tert-butyl (3-(2-((tert-butoxycarbonyl)amino)pyridin-4-yl)-3-(5-chloro-2-cyanophenoxy) propyl) (methyl) carbamate (357 mg, 0.69 mmol) in DCM (10 mL) was added Trifluoroacetic acid (10 mL) at 0 C. and the mixture was stirred at room temperature for 1.5 hrs. The solvent was removed under reduced pressure to give 2-(1-(2-aminopyridin-4-yl)-3-(methylamino) propoxy)-4-chlorobenzonitrile (6) (218.6 mg, 100% yield) as yellow oil. LCMS: m/z 317.1 [M+H]+.

Step 6. Synthesis of tert-butyl (3-(2-aminopyridin-4-yl)-3-(5-chloro-2-cyanophenoxy) propyl) (methyl) carbamate (7)

##STR00039##

[0092] To a mixture of 2-(1-(2-aminopyridin-4-yl)-3-(methylamino) propoxy)-4-chloro benzonitrile (174.86 mg, 0.552 mmol (80% purity)) in THF (10 mL) was added triethylamine to adjust the pH of the mixture to 8-9. Then Boc20 (120 mg, 0.552 mmol) was added at room temperature and the mixture was stirred at room temperature for 2 hrs. The mixture was purified on silica flash chromatography with a gradient of MeOH/DCM (0 to 10 percent) to give tert-butyl (3-(2-aminopyridin-4-yl)-3-(5-chloro-2-cyanophenoxy) propyl) (methyl) carbamate (7) mg, 0.6 mmol, 89.5% yield, (LCMS purity>93%)] as yellow oil. LCMS: m/z 417.0 [M+H]+. 1H NMR(400 MHZ, MeOD) 7.87 (d, J=6.4 Hz, 1H), 7.68 (d, J=8.4 Hz, 1H), 7.15 (s, 1H), 7.11-7.02 (m, 1H), 6.92-6.90 (m, 2H), 5.54-5.52 (m, 1H), 3.76-3.52 (m, 2H), 2.89 (s, 3H), 2.22-2.20 (m, 2H), 1.33 (s, 9H).

Step 7. Synthesis of tert-butyl (3-(5-chloro-2-cyanophenoxy)-3-(imidazo[1,2-a]pyridin-7-yl) propyl) (methyl) carbamate (8)

##STR00040##

[0093] A mixture of tert-butyl (3-(2-aminopyridin-4-yl)-3-(5-chloro-2-cyanophenoxy) propyl) (methyl) carbamate (180 mg, 0.432 mmol) and aqueous of 2-chloroacetaldehyde (6.1 Mol/L, 0.085 mL, 0.518 mmol) in EtOH (10 mL) in a sealed tube was stirred at 70 C. for 12 hrs. The solvent was removed and the residue was purified on silica flash chromatography with a gradient of EtOAc in Petroleum ether (0% to 100%) and then MeOH/DCM (0 to 10 percent) to give of tert-butyl (3-(5-chloro-2-cyanophenoxy)-3-(imidazo[1,2-a]pyridin-7-yl) propyl) (methyl) carbamate (150 mg, 0.341 mmol, 78.9% yield) (8) as yellow oil. LCMS: m/z 441.1 [M+H]+. 1H NMR(400 MHZ, MeOD) 8.49 (d, J=7.2 Hz, 1H), 7.86 (s, 1H), 7.67-7.58 (m, 3H), 7.18-7.16 (m, 1H), 7.07-7.05 (m, 2H), 5.65-5.60 (m, 1H), 3.60-3.52 (m, 2H), 2.90 (s, 3H), 2.34-2.32 (m, 1H), 2.19-2.16 (m, 1H), 1.36-1.31 (m, 9H).

Step 8. Synthesis of 4-chloro-2-(1-(imidazo[1,2-a]pyridin-7-yl)-3-(methylamino) propoxy)benzonitrile hydrogen chloride (CPG-200)

##STR00041##

[0094] To a solution of tert-butyl (3-(5-chloro-2-cyanophenoxy)-3-(imidazo[1,2-a]pyridin-7-yl) propyl) (methyl) carbamate (140 mg, 0.318 mmol) in MeOH (5 mL) was added a solution of HCl in dioxane (4M, 10 mL, 40 mmol) at 0 C. and the mixture was stirred at room temperature for 1 hr. The solvent was removed and the residue was purified by prep-HPLC (Fluent with 10 mM NH4HCO3 and ACN) to give 4-chloro-2-(1-(imidazo[1,2-a]pyridin-7-yl)-3-(methylamino) propoxy)benzonitrile as yellow syrup. LCMS: m/z 341.1.1 [M+H]+. 1H NMR(400 MHZ, MeOD) 8.50 (d, J=7.2 Hz, 1H), 7.85 (s, 1H), 7.63 (d, J=8.4 Hz, 1H), 7.60 (d, J=4.8 Hz, 2H), 7.17 (d,J=1.6 Hz, 1H), 7.09 (dd, J=8.4, 1.6 Hz, 1H), 7.00 (dd, J=7.2, 1.6 Hz, 1H), 5.74 (dd, J=8.4, 4.4 Hz, 1H), 3.08-2.96 (m, 2H), 2.57 (s, 3H), 2.47-2.35 (m, 1H), 2.31-2.22 (m, 1H).

Synthesis of ((R)-3-((6-chloro-1H-benzo[d]imidazol-4-yl)oxy)-3-phenylpropan-1-amine (CPG-224)

##STR00042##

Step 1. Synthesis of 5-chloro-3-methoxybenzene-1,2-diamine (2)

##STR00043##

[0095] A mixture of 4-chloro-2-methoxy-6-nitroaniline (10 g, 49.5 mmol), Fe powder (27.7 g, 495 mmol) and NH.sub.4Cl (26.5 g, 495 mmol) in 95% ethanol (250 mL) was stirred at 80 C. overnight carefully. LCMS was used to monitor this reaction. Filtered, the filtrate was purified by silica gel chromatography (EA/PE from 10% to 50%) to get 5-chloro-3-methoxy benzene-1,2-diamine (7 g, 82% yield) as brown solid. LCMS: m/z 173.1 [M+H]+.

Step 2. 6-chloro-4-methoxy-1H-benzo[d]imidazolediamine (3)

##STR00044##

[0096] A solution of 5-chloro-3-methoxybenzene-1,2-diamine (2 g, 11.6 mmol), methyl orthoformate (1.48 g, 14 mmol) and conc. H2SO4 (57 mg, 0.58 mmol) in methanol (50 mL) was stirred at room temperature for 1 h. LCMS was used to monitor this reaction. The solvent was evaporated, and the residue was partitioned between water (30 mL) and EtOAc (50 mL). The organic phase was separated, washed with water (30 mL) and brine (30 mL), dried over anhydrous Na2SO4 and concentrated, purified by column chromatography on silica gel (PE/EA from 0/1 to 1/1) to get 6-chloro-4-methoxy-1H-benzo[d]imidazole (1.9 g, 90% yield) as brown solid. LCMS: m/z 183.0 [M+H]+.

Step 3. 6-chloro-1H-benzo[d]imidazol-4-ol (4)

##STR00045##

[0097] A mixture of 6-chloro-4-methoxy-1H-benzo[d]imidazole (1.5 g, 8.24 mmol) in HBr/H2O (48%, 30 mL) was stirred at 120 C. for 4 days. LCMS was used to monitor this reaction. The solvent was evaporated, water (20 mL) was added, neutralized with sat. aq. NaHCO3, and filtered. The filter cake was dried in vacuo to get 6-chloro-1H-benzo[d]imidazol-4-ol (1.2 g, 87% yield) as brown solid. LCMS: m/z 169.0 [M+H]+.

Step 4. (R)-6-chloro-4-(3-chloro-1-phenylpropoxy)-1H-benzo[d]imidazole (5)

##STR00046##

[0098] To a solution of 6-chloro-1H-benzo[d]imidazol-4-ol (1.98 g, 11.8 mmol), (S)-3-chloro-1-phenylpropan-1-ol (2.0 g, 11.8 mmol) and PPh3 (3.1 g, 11.8 mmol) in THF (50 mL) was added DEAD (2.05 g, 11.8 mmol) dropwise at 0 C. under N.sub.2 balloon. The reaction was allowed to warm to room temperature and stirred overnight. The reaction solution was purified by column chromatography on silica gel (EA/PE from 1/10 to 1/4) to afford the pure product (2.36 g, 62% yield) as a white solid. LCMS: m/z 321.1 [M+H]+.

Step 5. Synthesis of (R)-3-((6-chloro-1H-benzo[d]imidazol-4-yl)oxy)-3-phenyl propan-1-amine (CPG-224)

##STR00047##

[0099] A mixture of (R)-6-chloro-4-(3-chloro-1-phenylpropoxy)-1H-benzo[d]imidazole (100 mg, 0.311 mmol), sodium iodide (4.7 mg, 0.031 mmol) in NH3/EtOH (3 mL) was stirred at 70 C. in a sealed tube for 16 hrs. The mixture was purified on prep-HPLC (0.1% formic acid/MeCN) to give (R)-3-((6-chloro-1H-benzo[d]imidazol-4-yl)oxy)-3-phenylpropan-1-amine (31.2 mg, 0.103 mmol) as the brown oil. LCMS: m/z 302.10 [M+H]+. 1HNMR(400 MHZ, MeOD) 8.52 (s, 1H), 8.20 (s, 1H) 7.45-7.41 (d, J=7.2 Hz, 2H), 7.37 (t, J=7.6 Hz, 2H), 7.31 (t, J=7.2 Hz, 1H), 7.16 (d, J=1.6 Hz, 1H), 6.56 (s, 1H), 5.64 (m, 1H), 3.28-3.22 (m, 2H), 2.47-2.37 (m, 1H), 2.29-2.24 (m, 1H).

Synthesis of (R)-3-((6-chloro-1H-benzo[d]imidazol-4-yl)oxy)N-methyl-3-phenyl propan-1-amine (CPG-255)

##STR00048##

Step 1. Synthesis of 5-chloro-3-methoxybenzene-1,2-diamine (2)

##STR00049##

[0100] A mixture of 4-chloro-2-methoxy-6-nitroaniline (10 g, 49.5 mmol), Fe powder (27.7 g, 495 mmol) and NH4Cl (26.5 g, 495 mmol) in 95% ethanol (250 mL) was stirred at 800C overnight carefully. LCMS was used to monitor this reaction. Filtered, the filtrate was purified by silica gel chromatography (EA/PE from 10% to 50%) to get 5-chloro-3-methoxy benzene-1,2-diamine (7 g, 82% yield) as brown solid. LCMS: m/z 173.1 [M+H]+.

Step 2. 6-chloro-4-methoxy-1H-benzo[d]imidazolediamine (3)

##STR00050##

[0101] A solution of 5-chloro-3-methoxybenzene-1,2-diamine (2 g, 11.6 mmol), methyl orthoformate (1.48 g, 14 mmol) and conc. H2SO.sub.4 (57 mg, 0.58 mmol) in methanol (50 mL) was stirred at room temperature for 1 h. LCMS was used to monitor this reaction. The solvent was evaporated, and the residue was partitioned between water (30 mL) and EtOAc (50 mL). The organic phase was separated, washed with water (30 mL) and brine (30 mL), dried over anhydrous Na.sub.2SO.sub.4 and concentrated, purified by column chromatography on silica gel (PE/EA from 0/1 to 1/1) to get 6-chloro-4-methoxy-1H-benzo[d]imidazole (1.9 g, 90% yield) as brown solid. LCMS: m/z 183.0 [M+H]+.

Step 3. 6-chloro-1H-benzo[d]imidazol-4-ol (4)

##STR00051##

[0102] A mixture of 6-chloro-4-methoxy-1H-benzo[d]imidazole (1.5 g, 8.24 mmol) in HBr/H2O (48%, 30 mL) was stirred at 120 C. for 4 days. LCMS was used to monitor this reaction. The solvent was evaporated, water (20 mL) was added, neutralized with sat. aq. NaHCO.sub.3. Filtered, the filter cake was dried in vacuo to get 6-chloro-1H-benzo[d]imidazol-4-ol (1.2 g, 87% yield) as brown solid. LCMS: m/z 169.0 [M+H]+.

Step 4. (R)-6-chloro-4-(3-chloro-1-phenylpropoxy)-1H-benzo[d]imidazole (5)

##STR00052##

[0103] To a solution of 6-chloro-1H-benzo[d]imidazol-4-ol (1.98 g, 11.8 mmol), (S)-3-chloro-1-phenylpropan-1-ol (2.0 g, 11.8 mmol) and PPh3 (3.1 g, 11.8 mmol) in THF (50 mL) was added DEAD (2.05 g, 11.8 mmol) dropwise at 0 C. under N.sub.2 balloon. The reaction was allowed to warm to room temperature and stirred overnight. The reaction solution was purified by column chromatography on silica gel (EA/PE from 1/10 to 1/4) to afford the pure product (2.36 g, 62% yield) as a white solid. LCMS: m/z 321.1 [M+H]+.

Step 5. (R)-3-((6-chloro-1H-benzo[d]imidazol-4-yl)oxy)N-methyl-3-phenylpropan-1-amine (CPG-255)

##STR00053##

[0104] A mixture of (R)-6-chloro-4-(3-chloro-1-phenylpropoxy)-1H-benzo[d]imidazole (100 mg, 0.311 mmol), sodium iodide (5 mg, 0.033 mmol) in MeNH2/EtOH (3 mL) was stirred at 70 C. in a sealed tube for 16 hrs. The mixture was purified on prep-HPLC (0.1% formic acid/MeCN) to give (R)-3-((6-chloro-1H-benzo[d]imidazol-4-yl)oxy)N-methyl-3-phenylpropan-1-amine (CPG-255) (71.4 mg, 72.6% yield) as the brown oil. LCMS: m/z 316.11 [M+H]+. 1HNMR(400 MHZ, MeOD) 8.53 (s, 1H), 8.22 (s, 1H), 7.45-7.43 (d, J=7.2 Hz, 2H), 7.40-7.36 (t, J=7.6 Hz, 2H), 7.33-7.30 (t, J=7.2 Hz, 1H), 7.18 (d, J=1.6 Hz, 1H), 6.55-6.54 (d, J=1.6 Hz, 1H), 5.62-5.59 (m, 1H), 3.39-3.28 (m, 2H), 2.77 (s, 3H), 2.49-2.40 (m, 1H), 2.33-2.24 (m, 1H).

Synthesis of (R)-3-((6-chloro-1H-indazol-4-yl)oxy)N-methyl-3-phenylpropan-1-amine (CPG-256)

##STR00054##

Step 1. Synthesis of 4-bromo-6-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (2)

##STR00055##

[0105] To a solution of 4-bromo-6-chloro-1H-indazole (3 g, 13 mmol) and TsOH (224 mg, 1.3 mmol) in DCM (30 mL) was added 3,4-dihydro-2H-pyran (2.18 g, 26 mmol) dropwise at ice-bath. Then, the reaction was stirred at room temperature for 4 h. LCMS was used to monitor this reaction. The reaction mixture was partitioned between sat. aq NaHCO3 (30 mL) and EtOAc (100 mL). The organic phase was separated, washed with water (30 mL) and brine (30 mL), dried over anhydrous Na2SO4 and concentrated, purified by column chromatography on silica gel (PE/EA from 0/1 to 1/1) to get 4-bromo-6-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (3 g, 75% yield) as a pale solid. LCMS: m/z 315.0 [M+H]+.

Step 2. Synthesis of 6-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-ol (3)

##STR00056##

[0106] A mixture of 4-bromo-6-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (3.8 g, 12.1 mmol), Pd3 (dba).sub.2 (219 mg, 0.24 mmol), tBuXPhos (259 mg, 0.05 mmol) and KOH (2.71 g, 48.4 mmol) in dioxane (30 mL) and water (30 mL) was stirred at reflux for 2 h. LCMS was used to monitor this reaction. The reaction mixture neutralized with 1N HCl, extracted with EtOAc (30 mL*3). The organic phase was separated, washed with water (30 mL) and brine (30 mL), dried over anhydrous Na.sub.2SO.sub.4 and concentrated, purified by column chromatography on silica gel (PE/EA from 0/1 to 1/1) to get 6-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-ol (2.3 g, 80% yield) as pale solid. LCMS: m/z 253.1 [M+H]+.

Step 3. Synthesis of 6-chloro-4-((R)-3-chloro-1-phenylpropoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (4)

##STR00057##

[0107] To a solution of 6-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-ol (2.97 g, 11.8 mmol), SM2 (2.0 g, 11.8 mmol) and PPh3 (3.1 g, 11.8 mmol) in THF (50 mL) was added DEAD (2.05 g, 11.8 mmol) dropwise at 0 C. under N.sub.2 balloon. The reaction was allowed to warm to room temperature and stirred overnight. The reaction solution was purified by column chromatography on silica gel (EA/PE from 1/10 to 1/1) to afford 6-chloro-4-((R)-3-chloro-1-phenylpropoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (2.36 g, 50% yield) as a white solid. LCMS: m/z 405.1 [M+H]+.

Step 4. Synthesis of (R)-6-chloro-4-(3-chloro-1-phenylpropoxy)-1H-indazole (5)

##STR00058##

[0108] To a solution of 6-chloro-4-((R)-3-chloro-1-phenylpropoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (2.36 g, 9.374 mmol) in DCM (20 mL) was added TFA (10 mL) dropwise at 0 C. The reaction was allowed to warm to room temperature and stirred overnight. The solvent was evaporated to afford (R)-6-chloro-4-(3-chloro-1-phenylpropoxy)-1H-indazole (2.5 g, 100% yield) as brown oil. LCMS: m/z 321.1 [M+H]+.

Step 5. Synthesis of (R)-3-((6-chloro-1H-indazol-4-yl)oxy)N-methyl-3-phenylpropan-1-amine (CPG-256)

##STR00059##

[0109] A mixture of (R)-6-chloro-4-(3-chloro-1-phenylpropoxy)-1H-indazole (200 mg, 0.623 mmol), sodium iodide (10 mg, 0.067 mmol) in MeNH2/EtOH (4 mL) was stirred at 70 C. in a sealed tube for 16 hrs. The mixture was purified on prep-HPLC (0.1% formic acid/MeCN) to give synthesis of (R)-3-((6-chloro-1H-indazol-4-yl)oxy)N-methyl-3-phenylpropan-1-amine (CPG-256). (59.9 mg, 30.5% yield) as the yellow oil. LCMS: m/z 316.11 [M+H]+. 1H NMR (400 MHZ, DMSO) 8.37 (s, 1H), 8.16 (d, J=0.7 Hz, 1H), 7.45 (d, J=7.2 Hz, 2H), 7.37 (t, J=7.5 Hz, 2H), 7.28 (t, J=7.3 Hz, 1H), 7.11 (s, 1H), 6.43 (d, J=1.2 Hz, 1H), 5.71 (m, 1H), 2.83 (t, J=7.3 Hz, 2H), 2.42 (s, 3H), 2.25 (m, 1H), 2.09 (m, 1H).

Synthesis of (R)-2-((3-((6-chloro-1H-benzo[d]imidazol-4-yl)oxy)-3-phenylpropyl)amino) ethan-1-ol (CPG-257)

##STR00060##

Step 1. Synthesis of 5-chloro-3-methoxybenzene-1,2-diamine (2)

##STR00061##

[0110] A mixture of 4-chloro-2-methoxy-6-nitroaniline (10 g, 49.5 mmol), Fe powder (27.7 g, 495 mmol) and NH.sub.4Cl (26.5 g, 495 mmol) in 95% ethanol (250 mL) was stirred at 80 C. overnight carefully. LCMS was used to monitor this reaction. Filtered, the filtrate was purified by silica gel chromatography (EA/PE from 10% to 50%) to get 5-chloro-3-methoxy benzene-1,2-diamine (7 g, 82% yield) as brown solid. LCMS: m/z 173.1 [M+H]+.

Step 2. 6-chloro-4-methoxy-1H-benzo[d]imidazolediamine (3)

##STR00062##

[0111] A solution of 5-chloro-3-methoxybenzene-1,2-diamine (2 g, 11.6 mmol), methyl orthoformate (1.48 g, 14 mmol) and conc. H2SO.sub.4 (57 mg, 0.58 mmol) in methanol (50 mL) was stirred at room temperature for 1 h. LCMS was used to monitor this reaction. The solvent was evaporated, and the residue was partitioned between water (30 mL) and EtOAc (50 mL). The organic phase was separated, washed with water (30 mL) and brine (30 mL), dried over anhydrous Na.sub.2SO.sub.4 and concentrated, purified by column chromatography on silica gel (PE/EA from 0/1 to 1/1) to get 6-chloro-4-methoxy-1H-benzo[d]imidazole (1.9 g, 90% yield) as brown solid. LCMS: m/z 183.0 [M+H]+.

Step 3. 6-chloro-1H-benzo[d]imidazol-4-ol (4)

##STR00063##

[0112] A mixture of 6-chloro-4-methoxy-1H-benzo[d]imidazole (1.5 g, 8.24 mmol) in HBr/H2O (48%, 30 mL) was stirred at 120 C. for 4 days. LCMS was used to monitor this reaction. The solvent was evaporated, water (20 mL) was added, neutralized with sat. aq. NaHCO3. Filtered, the filter cake was dried in vacuo to get 6-chloro-1H-benzo[d]imidazol-4-ol (1.2 g, 87% yield) as brown solid. LCMS: m/z 169.0 [M+H]+.

Step 4. (R)-6-chloro-4-(3-chloro-1-phenylpropoxy)-1H-benzo[d]imidazole (5)

##STR00064##

[0113] To a solution of 6-chloro-1H-benzo[d]imidazol-4-ol (1.98 g, 11.8 mmol), (S)-3-chloro-1-phenylpropan-1-ol (2.0 g, 11.8 mmol) and PPh3 (3.1 g, 11.8 mmol) in THF (50 mL) was added DEAD (2.05 g, 11.8 mmol) dropwise at 0 C. under N.sub.2 balloon. The reaction was allowed to warm to room temperature and stirred overnight. The reaction solution was purified by column chromatography on silica gel (EA/PE from 1/10 to 1/4) to afford the pure product (2.36 g, 62% yield) as a white solid. LCMS: m/z 321.1 [M+H]+.

Step 5. (R)-2-((3-((6-chloro-1H-benzo[d]imidazol-4-yl)oxy)-3-phenylpropyl)amino) ethan-1-ol (CPG-257)

##STR00065##

[0114] A mixture of (R)-6-chloro-4-(3-chloro-1-phenylpropoxy)-1H-benzo[d]imidazole (100 mg, 0.311 mmol), 2-aminoethan-1-ol (95 mg, 1.555 mmol) and sodium iodide (5 mg, 0.033 mmol) in EtOH (2 mL) was stirred at 70 C. in a sealed tube for 16 hrs. The mixture was purified on prep-HPLC (0.1% formic acid/MeCN) to give (R)-2-((3-((6-chloro-1H-benzo[d]imidazol-4-yl)oxy)-3-phenylpropyl)amino) ethan-1-ol (CPG-257) (69.9 mg, 64.9% yield) as the yellow oil. LCMS: m/z 346.12 [M+H]+. 1H NMR(400 MHZ, DMSO) 8.32 (s, 1H), 8.21 (s, 1H), 7.44 (d, J=7.3 Hz, 2H), 7.36 (t, J=7.5 Hz, 2H), 7.27 (t, J=7.2 Hz, 1H), 7.19 (d, J=1.6 Hz, 1H), 6.64 (d, J=1.5 Hz, 1H), 5.81 (dd, J=8.2, 4.5 Hz, 1H), 3.57 (t, J=5.4 Hz, 2H), 2.93 (s, 2H), 2.81 (t, J=5.5 Hz, 2H), 2.24 (dt, J=14.0, 7.8 Hz, 1H), 2.11 (dd, J=12.5, 7.6 Hz, 1H).

Synthesis of (R)-2-((3-((6-chloro-1H-indazol-4-yl)oxy)-3-phenylpropyl)amino) ethan-1-ol (CPG-258)

##STR00066##

Step 1. Synthesis of 4-bromo-6-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (2)

##STR00067##

[0115] To a solution of 4-bromo-6-chloro-1H-indazole (3 g, 13 mmol) and TsOH (224 mg, 1.3 mmol) in DCM (30 mL) was added 3,4-dihydro-2H-pyran (2.18 g, 26 mmol) dropwise at ice-bath. Then, the reaction was stirred at room temperature for 4 h. LCMS was used to monitor this reaction. The reaction mixture was partitioned between sat. aq. NaHCO.sub.3 (30 mL) and EtOAc (100 mL). The organic phase was separated, washed with water (30 mL) and brine (30 mL), dried over anhydrous Na.sub.2SO.sub.4 and concentrated, purified by column chromatography on silica gel (PE/EA from 0/1 to 1/1) to get 4-bromo-6-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (3 g, 75% yield) as a pale solid. LCMS: m/z 315.0 [M+H]+.

Step 2. Synthesis of 6-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-ol (3)

##STR00068##

[0116] A mixture of 4-bromo-6-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (3.8 g, 12.1 mmol), Pd3 (dba).sub.2 (219 mg, 0.24 mmol), tBuXPhos (259 mg, 0.05 mmol) and KOH (2.71 g, 48.4 mmol) in dioxane (30 mL) and water (30 mL) was stirred at reflux for 2 h. LCMS was used to monitor this reaction. The reaction mixture neutralized with 1N HCl, extracted with EtOAc (30 mL*3). The organic phase was separated, washed with water (30 mL) and brine (30 mL), dried over anhydrous Na.sub.2SO.sub.4 and concentrated, purified by column chromatography on silica gel (PE/EA from 0/1 to 1/1) to get 6-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-ol (2.3 g, 80% yield) as pale solid. LCMS: m/z 253.1 [M+H]+.

Step 3. Synthesis of 6-chloro-4-((R)-3-chloro-1-phenylpropoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (4)

##STR00069##

[0117] To a solution of 6-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-ol (2.97 g, 11.8 mmol), SM2 (2.0 g, 11.8 mmol) and PPh3 (3.1 g, 11.8 mmol) in THF (50 mL) was added DEAD (2.05 g, 11.8 mmol) dropwise at 0 C. under N.sub.2 balloon. The reaction was allowed to warm to room temperature and stirred overnight. The reaction solution was purified by column chromatography on silica gel (EA/PE from 1/10 to 1/1) to afford 6-chloro-4-((R)-3-chloro-1-phenylpropoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (2.36 g, 50% yield) as a white solid. LCMS: m/z 405.1 [M+H]+.

Step 4. Synthesis of (R)-6-chloro-4-(3-chloro-1-phenylpropoxy)-1H-indazole (5)

##STR00070##

[0118] To a solution of 6-chloro-4-((R)-3-chloro-1-phenylpropoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (2.36 g, 9.374 mmol) in DCM (20 mL) was added TFA (10 mL) dropwise at 0 C. The reaction was allowed to warm to room temperature and stirred overnight. The solvent was evaporated to afford (R)-6-chloro-4-(3-chloro-1-phenylpropoxy)-1H-indazole (2.5 g, 100% yield) as brown oil. LCMS: m/z 321.1 [M+H]+.

Step 5. Synthesis of (R)-2-((3-((6-chloro-1H-indazol-4-yl)oxy)-3-phenylpropyl)amino) ethan-1-ol (CPG-258)

##STR00071##

[0119] A mixture of (R)-6-chloro-4-(3-chloro-1-phenylpropoxy)-1H-indazole (200 mg, 0.623 mmol), 2-aminoethan-1-ol (190 mg, 3.111 mmol), and sodium iodide (10 mg, 0.067 mmol) in EtOH (3 mL) was stirred at 70 C. in a sealed tube for 16 hrs. The mixture was purified on prep-HPLC (0.1% formic acid/MeCN) to give (R)-2-((3-((6-chloro-1H-indazol-4-yl)oxy)-3-phenylpropyl)amino) ethan-1-ol (CPG-258) (71.3 mg, 33.1% yield) as the yellow oil. LCMS: m/z 346.12 [M+H]+. 1H NMR(400 MHZ, MeOD) 8.52 (s, 1H), 8.17 (d, J=0.4 Hz, 1H), 7.46 (d, J=7.2 Hz, 2H), 7.39 (t, J=7.6 Hz, 2H), 7.31 (t, J=7.2 Hz, 1H), 7.08 (s, 1H), 6.37 (d, J=1.2 Hz, 1H), 5.62 (m, 1H), 3.80-3.76 (m, 2H), 3.37-3.32 (m, 1H), 3.28-3.21 (m, 1H), 3.17-3.12 (m, 2H), 2.53-2.43 (m, 1H), 2.34 (m, 1H).

Synthesis of 2-(3-amino-1-(2-aminopyridin-4-yl) propoxy)-4-chlorobenzonitrile (CPG-263)

From CPG-195

##STR00072##

[0120] A mixture of 2-(1-(2-aminopyridin-4-yl)-3-(1,3-dioxoisoindolin-2-yl) propoxy)-4-chlorobenzonitrile (150 mg, 0.347 mmol), hydrazine hydrate (0.5 mL, 10.3 mmol) in EtOH (10 mL) was stirred at 80 C. for 12 hrs. The solvent was removed and the residue was purified by Prep-HPLC (Fluent with 10 mM NH4HCO3 and ACN) to give 2-(3-amino-1-(2-amino pyridin-4-yl) propoxy)-4-chlorobenzonitrile (CPG-263) (27.5 mg, 0.091 mmol, 26.2% yield) as a white solid. LCMS: m/z 303.0 [M+H]+1HNMR(400 MHZ, MeOD) 7.89 (d, J=5.6 Hz, 1H), 7.63 (d, J=8.4 Hz, 1H), 7.09 (dd, J=8.4, 1.6 Hz, 1H), 6.99 (d, J=1.6 Hz, 1H), 6.62 (dd, J=5.6, 1.6 Hz, 1H), 6.57 (s, 1H), 5.47 (dd, J=8.4, 4.4 Hz, 1H), 2.94 (t, J=7.2 Hz, 2H), 2.27-2.18 (m, 1H), 2.14-2.04 (m, 1H).

Synthesis of (R)-2-(3-((6-chloro-1H-indazol-4-yl)oxy)-3-phenylpropyl) isoindoline-1,3-dione (CPG-265)

##STR00073##

[0121] A mixture of (R)-6-chloro-4-(3-chloro-1-phenylpropoxy)-1H-indazole (321.2 mg, 1.0 mmol) in DMF (5 mL) in a sealed tube was stirred at 90 C. for 1 h. The mixture was purified on prep-HPLC (Fluent with 0.2% Formic acid and ACN) to give (R)-2-(3-((6-chloro-1H-indazol-4-yl)oxy)-3-phenylpropyl) isoindoline-1,3-dione (CPG-265) (22.3 mg, 0.052 mmol, 5.2% yield) as a white solid. LCMS: m/z 432.1 [M+H]+. 1HNMR(400 MHZ, MeOD) 7.81 (s, 1H), 7.75-7.68 (m, 4H), 7.41 (d, J=7.2 Hz, 2H), 7.31 (t, J=7.6 Hz, 2H), 7.22 (t, J=7.2 Hz, 1H), 6.98 (s, 1H), 6.28 (d, J=1.2 Hz, 1H), 5.55 (dd, J=8.8, 3.6 Hz, 1H), 4.08-3.99 (m, 1H), 3.98-3.88 (m, 1H), 2.52-2.48 (m, 1H), 2.35-2.16 (m, 1H).

Example 3: IC50 of Compounds of Formula (I-6)

[0122] The IC50 of some compounds of the invention was determined using the abcam NOS Inhibitor Screening Kit. The procedure includes the following steps: (1) Dissolved a test compound to 10 mM in DMSO; (2) Diluted the test compound to 1 mM in NOS Assay Buffer; (3) Diluted 1 mM of the test compound stocks to 200 M, 50 M, 12.5 M, 3.125 M, 0.781 M, and 0.195 M in NOS Assay Buffer; (4) Diluted 1 mM DPI Control to 50.0 M, 12.5 M, 3.125 M, 0.781 M, 0.195 M, and 0.0488 M in NOS Assay Buffer; (5) Diluted NOS enzyme with 400 L of NOS Assay Buffer; (6) Combined Diluted NOS Enzyme with 1.6 mL of NOS Assay buffer then transferred 20 L of enzyme solution to all wells of 96-well Fluorescence plate except background wells. Added 20 L of NOS Assay buffer to background wells. (7) Transferred 10 L of each test compound dilution to the enzyme buffer mix according to the plate map (see addendum for plate map and raw data values). (8) Incubated 15 minutes at room temperature. (9) Added 11 L of NOS reaction mix (according to manufacturer's protocol) to each well, mixed, and incubated at 37 C. for 1 hour. (10) Added 110 L of NOS Assay Buffer to each well followed by 5 L of Enhancer to each well, mixed, and incubated 10 minutes at room temperature; (11) Added 10 L of Probe to each well, mixed, and incubated 10 minutes at room temperature; and (12) Added 5 L of NaOH to each well, mixed, and incubated 10 minutes at room temperature. Measure Fluorescence at 360 nm excitation/450 nm emission.

[0123] The IC50 results of Formula (I-6) compounds are tabulated in Table C-1 below.

TABLE-US-00004 TABLE C-1 GT-ID IC50 (M) GT-6041 0.156 GT-6045 0.231 GT-6058 0.457 GT-6059 0.252 GT-6060 0.444 GT-6064 0.0285 GT-6065 0.0678 GT-6066 0.27

[0124] Given that Compound AZ 6b has an IC50 of 0.0488 M, the following compounds of the invention in Table C-2 demonstrate promising result for prophylaxis and/or treatment of a disorder or disease mediated by iNOS or associated with aberrant iNOS activity.

TABLE-US-00005 TABLE C-2 GT-ID IC50 (uM) Fold (GT-xxxx)/AZ 6b GT-6064 0.0285 0.58 GT-6065 0.0678 1.39 GT-6041 0.156 3.20 GT-6045 0.231 4.73 GT-6059 0.252 5.16 GT-6066 0.27 5.53 GT-6060 0.444 9.10 GT-6058 0.457 9.36

Example 4: Kinetic Solubility Assay

[0125] The development of novel oral anti-cancer drugs requires that compounds exhibit adequate aqueous solubility to ensure effective gastrointestinal dissolution and systemic bioavailability.

[0126] Our kinetic solubility assay, employing 10 mM DMSO stock solutions and an HPLC-based external standard method, evaluated some representative compounds. This kinetic solubility assay assesses our compounds in pH 7.4 PBS, mimicking physiological conditions relevant to oral absorption and tumor targeting. Test solutions were prepared by mixing 10 L of stock with 490 L of PBS (pH 7.4, 2% DMSO), followed by shaking at 37 C. for 3 hours, centrifugation, and a 2 dilution with methanol. Solubility was quantified in M using HPLC analysis on a C18 column at 35 C., with a 5-85% acetonitrile gradient and 20 L injections, performed in duplicate.

[0127] The assay was conducted using a modified HPLC-based external standard method. For Solution Preparation, (1) Buffer: Phosphate-buffered saline (PBS) at pH 7.4; (2) Compound Stock Solutions: 10 mM concentration in DMSO; (3) Test Solutions: Mix 10 L of the stock solution with 490 L of PBS in a 2 mL EP tube (final 2% DMSO v/v), shake at 37 C. for 3 hours, centrifuge at 12,000 RPM for 5-10 minutes, take 100 L of supernatant, add 100 L methanol, mix well to use as the test solution. For Chromatographic Analysis, (1) System: HPLC; (2) Column: C18, 3.5 m, dimensions 4.6150 mm or 4.6100 mm; (3) Mobile Phase: 0.01 M KH.sub.2PO.sub.4 (pH 2.5) and acetonitrile; (4) Gradient: Increase from 5% to 85% acetonitrile over 5 minutes; and (5) Injection Volume: 20 L volume, duplicate runs. For Data Analysis, concentration calculations are based on peak area ratios, accounting for the 2 dilution factor. The results for some representative compounds are listed in the table below.

TABLE-US-00006 GT-ID Solubility (M) GT-6041 156.62 GT-6058 176.58 GT-6059 169.3 GT-6060 175.72 GT-6045 188.41

[0128] The results for the five representative compounds, GT-6041, GT-6058, GT-6059, GT-6060, and GT-6045, demonstrated substantial solubility, with values ranging from 156.62 M to 188.41 M. This indicates robust potential for effective oral delivery and therapeutic concentration, making them promising candidates for further development. This indicates that these compounds possess robust aqueous solubility, crucial for ensuring effective gastrointestinal dissolution and achieving therapeutic concentrations in the bloodstream. Their favorable solubility profiles suggest strong potential for development into effective oral anti-cancer medications and serve as a strong indication of the promising nature of our broader compound library.

[0129] In the foregoing specification, embodiments of the present invention have been described with reference to numerous specific details that may vary from implementation to implementation. The specification and drawings are, accordingly, to be regarded in an illustrative rather than a restrictive sense. The sole and exclusive indicator of the scope of the invention, and what is intended by the applicant to be the scope of the invention, is the literal and equivalent scope of the set of claims that issue from this application, in the specific form in which such claims issue, including any subsequent correction.